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Abstract
RNA-binding proteins play critical role in the post-transcriptional processing of mRNAs. One 
such RNA binding protein is termed as the-Coding Region Determinant Binding Protein (CRD- 
BP). CRD-BP is an onco-fetal protein whose overexpression has been reported in various types 
of human cancers including, breast, colon, liver, skin, ovary, lung, brain, chorion, and testicular 
cancers. CRD-BP is a member o f VICKZ family of RNA-binding proteins. In many instances, 
RNA binding leads to stabilization of the transcripts and an increase in their corresponding 
protein levels; the result is manifest in downstream effects and the cancer phenotype.
The primary goal of this study was to obtain a better understanding of the interaction between 
CRD-BP and its three target mRNAs: GUI, MDR1 and CD44. Radiolabelled electrophoretic 
mobility shift assay (EMSA) was performed with [32P]-labeled truncated GLI1 and MDR1 RNAs 
to find smaller region of the transcripts which can still bind CRD-BP. It was found that G U I 
320-380 RNA is the minimum region required for binding CRD-BP, while, MDR1 779-881 
RNA is the minimum region which still has high affinity for CRD-BP.
Previous deletion studies of CRD-BP orthologs revealed that the KH domains, and not the 
RRM domains, are critical for binding RNA substrates. However, it was unclear as to what 
extent each KH domain plays nor is it known if different KH domains are important in binding 
different RNAs. In this study, I used site-directed mutagenesis to mutate the GXXG to DXXG in 
each of the KH domains as an approach to investigate the role of each KH domains, in the 
context of the entire protein, in binding G U I and MDR1 RNAs. The Kj values of all the single 
and double KH variants that are capable of binding to G U I and CD44 RNAs was determined. In 
general, it was found that single mutation in KH domains may or may not affect the binding 
affinity of transcript, while mutations at any two KH domains totally abrogated the binding of
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RNA to CRD-BP,with the exception of KH3-4 which binds CD44 RNA but not G U I RNA. This 
finding also supports the hypothesis that KH domains generally work in tandem. The results also 
clearly showed that different RNAs bind CRD-BP differently in vitro. The secondary goal of 
my thesis was to design RNA oligonucleotides capable o f breaking the specific CRD-BP-GT/7 
RNA interaction in vitro and in cells. For in vitro studies, competition studies using [ P] labelled 
G L I230-420 RNA and MFOLD designed RNA/DNA oligonucleotides were utilized. Amongst 
eight RNA oligonucleotides and one DNA oligonucleotide, SI RNA was the best competitor 
against [32P] labelled GLI 230-420 RNA in vitro. The T47D human breast cancer cell and 
HCT116 human colorectal cancer cell which expressed detectable level of G U I mRNA were 
chosen for further studies with the SI RNA oligonucleotide. In both T47D and HCT116 cells 
where CRD-BP-GI/7 mRNA interaction was demonstrated to exists, SI RNA oligonucleotide 
significantly and specifically down-regulate GLI1 mRNA expression. The results obtained 
support the model that CRD-BP protects G U I mRNA from degradation in T47D and HCT116 
cells, and suggest that breaking CRD-BP-GL/i mRNA interaction is a feasible approach to 
inhibit GLI1 expression.
In summary, this work shows that different mRNAs indeed bind to CRD-BP differently and it 
is feasible to design/discover molecules capable of breaking specific CRD-BP-RNA interaction 
in vitro. Most importantly, molecule that breaks CRD-BP-RNA interaction in vitro was also 
capable of down-regulating specific the mRNA in cells. This work has provided further evidence 
to support the development of a new class of anti-cancer drugs that act by breaking specific 
protein-RNA interaction.
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Chapter 1. Introduction 
Chapter 1
1.1 Background Information
According to the central dogma of molecular biology, genetic material flows from DNA to 
mRNA to protein (Figure 1). Numerous steps are involved to go from the DNA molecule to a 
functional protein within the cell. At the DNA level, many factors contribute to the transcription 
of a gene. Transcription factors bind directly to certain regions on the DNA molecule and 
regulate proteins that carry out the transcription itself. Gene expression can be controlled at 
many steps via multiple pathways. Functional proteins play a key role in cellular functions, and 
these include the control of gene expression.
Nucleus
Cytoplasm
ABflBBBflftaifr- 3 
_  mRNA
Translation
Growing'
protein''
Figure 1. Scheme of Central Dogma of Molecular Biology (Weiss and Buchanan, 2009)
1.2 The regulation of gene expression
Expression of a gene can be controlled at different levels, including transcription, mRNA
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stability, translation of RNA to protein, pre-mRNA splicing and post-translational events such as 
protein stability and modification (Day and Tuite, 1998). As my research is related to mature 
mRNAs, I will mainly focus on the post-transcriptional regulation of gene expression.
Post-transcriptional modifications to mRNA transcripts are essential to the generation of a 
functional mRNA transcript. The majority of eukaryotic mRNAs carry a 5’ 7-methylguanosine 
cap structure and a 3’ poly (A) tail comprising of about 200 adenosine residues in length, which 
protect the RNA chain from degradation by exonucleases. In addition to the cap and poly(A) tail 
with its associated poly(A)-binding protein (PABP), some specific internal sequence elements 
also influence intrinsic stability of mRNA (Day and Tuite, 1998). Such determinants can exert a 
destabilising effect on an mRNA and their location in transcripts is arbitrary. For instance, such 
determinants have been found in the 5’ UTR (Pierrat et al, 1993), in the 3’ UTR (Muhlrad et al, 
1992), and in the coding region (Herrick et al, 1992) of different mRNAs.
Another important mRNA processing step that controls gene expression is alternative splicing 
of pre-mRNAs. Alternative splicing is a fundamental mechanism found in many organisms 
including humans. Expression of proteins in humans is regulated by this important step. Upto 
95% of pre-mRNAs undergo splicing to produce mature mRNAs (Katzenberger et al, 2009).
The splicing patterns depend on the assembly of the spliceosome complex on the introns which 
are to be removed from pre-mRNA (Katzenberger et al, 2009). Five small nuclear 
ribonucleoproteins (snRNPs, U l, U2, U4, U5 and U6) along with multiple regulatory proteins 
carry out trans-esterification reactions that are responsible for the splicing (Katzenberger et al, 
2009). Such regulation of gene expression at the level of pre-mRNA can be complex; however, it 
is necessary for the expression of many variant proteins in cells.
1.3 The regulation of mRNA degradation
13
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The mRNA decay pathways will be discussed in this section. Gene expression is regulated at 
many Check points starting from DNA level and ending at protein level. In order to understand 
geneexpression, one must understand the cellular mechanisms that control the stability and 
turnover rate of mRNA (Anderson and Parker 1998). The degradation of mRNA transcripts 
depends on mRNA decay pathway as well as stability of the mRNA molecule (Farina et al 
2008). As mentioned earlier, the addition of the 5’ methyl-guanasine cap and the 3’ poly (A) tail 
consisting of multiple adenosine monophosphates are post-transcriptional modifications that can 
protect the transcript from nucleolytic attack by RNA degradative enzymes at the 5’ and 3’ ends 
of mRNA. However, the 5’ cap and 3’ poly A tail, and more recently, internal sequences are also 
important when it comes to the mRNA decay pathways.
1.3.1 The pathways of mRNA degradation
There are three well-described mRNA decay pathways, including the deadenylation- 
dependent pathway, decapping pathway and endonucleolytic pathway (Figure 2).
Figure 2. mRNA decay pathways (Gameau et al, 2008)
The current dogma suggests the 5’ decapping and the 3’ deadenylation-dependent pathways as 
the major pathways for the degradation of mRNA molecules. The endonucleolytic pathway has
5 'UTR ORf rU T R -AAAA
■ COK-NOT or PARN
Lsml-7
Cndonuchnw 
RNwrMRR)
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not been studied much, but it does seem to play a role in controlling of gene expression (Li et al. 
2010).
1.3.2 Cis-elements (5’UTR, coding region, 3’UTR)
Cis-regulatory elements are RNA sequences within a transcript that regulate expression of 
the corresponding transcript (Alberts et al, 2008). Although the role of the 5’ UTRs 
on mRNA stability is less clear, however in some cases this region can significantly affect 
specific mRNA half-lives. In theory, half-life of an mRNA is affected due to the influence of 5’ 
UTR on its translational efficiency (Ross, 1995). In addition, the length of the 5’ UTR also 
affects half-life of RNA as in the case of c-myc mRNA. This effect was shown to be independent 
of translation (Bonnieu et al, 1988).
c-myc mRNA contains a coding region instability determinant, or CRD, involved in message 
instability. However, it confers stability to c-myc mRNA upon binding to CRD-binding protein 
(CRD-BP). Regulatory RNA sequences present in the coding region are also found in some other 
transcripts such as c- fos and IL-2 (Knapinska et al, 2005). The c-myc CRD contains a higher 
than usual percentage of rare codons, that are responsible for ribosome pausing. This pausing 
leads to creation of a ribosome-free mRNA segment between the pause site and translation 
termination site. It is postulated that the exposed segments can be degraded by endoribonuclease 
during the translational pausing. The CRD’s stabilizing effect is dependent on translation of the 
CRD segment, and presence of stop codon just upstream of CRD can lead to increased mRNA 
decay even in the presence of CRD-BP (Lemm and Ross, 2002).
A+U rich element (ARE) is the best characterized family of instability determinants found in 
the 3’ UTR. These elements were first discovered as mediators of instability in transcripts coding 
for inflammatory responses proteins (Caput et al, 1986; Shaw and Kamen, 1986). AREs are now 
known to regulate a variety of transcripts via mRNA degradation and/or translational repression.
15
Chapter 1. Introduction
Deadenylating enzymes, the exosome, and the proteasome are involved in the degradation of 
ARE-containing mRNAs (Laroia et al, 1999; Chen et al, 2001). AREs are responsible for 
controlling the stability of many transcripts such as c-fos, c-myc, c-jun, COX-2, MMP-13, 
cyclins, Cdk inhibitors, DNA methyltransferase I, IL-lb, IL-3, TNFa, and many others (Audic 
and Hartley, 2004; Wilson et al, 2003).
Iron response element (IRE) is another example of a ds-regulatory element. IRE sequences are 
found in the 5’ or 3’ ends of mRNAs and after binding with iron regulatory proteins, they alter 
gene expression (Nelson and Cox, 2008).
1.3.3 Trans-acting factors (ribonucleases, miRNAs, RNA-binding proteins)
Ribonucleases are enzymes having the ability to catalyze the degradation of RNA molecules 
in an exoribonucleolytic and endoribonucleolytic manner. There are numerous ribonucleases and 
their classification is based on the mechanism employed to break RNA molecule.
Exoribonucleases are groups of ribonucleases that degrade the RNA molecules externally from 
either the 5’ or 3’ end (Farina et al, 2008). Conversely, endoribonucleases are groups of 
ribonucleases that catalyze the degradation of RNAs by attacking the molecule internally. 
Ribonucleases play an essential role in the degradation of mRNA transcripts and therefore the 
expression of genes.
miRNAs are small non-coding RNAs of approximately 22 nucleotides and are considered an 
important class of gene regulators. They are abundant in animals and plants, and after their genes 
are transcribed and processed like other premature RNAs, mature miRNAs bind target sites 
present on the mRNAs at the 3’UTR as well as in the coding region, leading to translational 
repression or degradation of mRNAs (Goswami et al, 2010). miRNAs can take part in acquired 
therapy resistance in cancer cells. One class of miRNAs acts by targeting survival pathways or 
pathways involved in apoptosis sensitivity (Boyerinas et al, 2010), whereas the second class
16
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modulates therapy by targeting those genes that are involved in metabolism or transport of drugs. 
Examples are: miR-200c that targets TUBB3 (Cochrane et al, 2009); miR-451 and miR-27a that 
target MDRl (Zhu et al, 2008); miR-24 that targets DHFR (Mishra et al, 2007); and miR 328 
and miR-519c that target ABCG2 (Pan et al, 2009; To et al, 2008).
Let-7 is a family of thirteen related miRNAs that are located on nine different chromosomes in 
humans. Let-7 is considered as tumor suppressor and its down-regulation leads to human 
cancer (Boyerinas et al, 2010).
As mentioned above, the post-transcriptional modifications of transcripts at the 5’ and 3’ end 
protects mRNAs from nucleolytic attack. Another important factor for mRNA protection is the 
RNA-binding proteins. RNA-binding proteins bind to mRNAs and protect them from nucleases 
(Mullen and MarzlufF, 2008). Although much work has been done on the regulation of gene 
transcription and expression, much less is known about the targets and roles of RNA-binding 
proteins (Hogan et al, 2008).
1.4 RNA binding proteins
Recent studies have shown the involvement of RNA binding proteins in the post- 
transcriptional processing of mRNAs. These proteins recognize specific sites of newly 
transcribed transcripts and their binding occurs at specific times during processing of mRNA 
transcript (Hogan et al, 2008). Hogan et al (2008) showed that a variety of motifs through which 
RNA binding proteins recognize and bind to (Figure 3). Trends found in these motifs may assist 
in the identification of new RNA motifs for other RNA-binding proteins.
17
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Figure 3. A variety of sequence motifs within mRNAs that are bound by RNA-binding proteins 
(Hogan et al, 2008).
RNA-binding proteins seem to have diverse roles in the cell, particularly in protecting the 
mRNAs from enzymatic attack. This has been observed in various diseases including diabetic 
retinopathy, coronary artery disease and tumor angiogenesis in cancers (Levy et al, 1998). 
Tumor angiogenesis is known to be essential for tumor growth and metastasis, and vascular 
endothelial growth factor (VEGF) is the most studied angiogenic factor known to be crucial for 
tumor growth (Levy et al, 1998). VEGF mRNA is post-transcriptionally regulated, namely by a 
specific RNA-binding protein.
HuR binds to the destabilising element at the 3’ UTR of VEGF mRNA under hypoxic 
conditions (Levy et al, 1998). This is an example which shows that RNA-binding proteins can be 
implicated in diseases such as cancer. My work focuses on the RNA-binding protein called the 
Coding Region Determinant-Binding Protein (CRD-BP) which is known to bind to a number of 
different mRNA targets implicated in cancers.
18
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1.5 Coding Region Determinant Binding Protein (CRD-BP)
CRD-BP belongs to VICKZ (Vgl, IMP1, 2, 3, CRD-BP, KOC, ZBP-1) family of RNA 
binding proteins. These proteins are highly conserved in vertebrates and have been shown to play 
critical role in the post-transcriptional control of gene expression, namely in mRNA stability, 
translation and localization (Yisraeli, 2005; Bell et al 2013).
1.5.1 Structure and function
The mouse coding region determinant binding protein (CRD-BP), composed of 577 amino 
acid and having four K-homology (KH) domains and two RNA recognition motifs (RRMs) 
(Figure 4) (Bell et al, 2013). CRD-BP was first discovered based on its high affinity to the 
coding region determinant of c-myc mRNA (Doyle et al, 1998). CRD-BP gene comprises of 
almost 40 Kb in length and contains 15 exons and 14 introns. In mice, it is located on 
chromosome 11 while in humans it is located on chromosome 17 (Doyle et al, 2000).
Figure 4. CRD-BP functional domain locations (Chao et al, 2010).
RRM consisting of two short consensus sequences RNP1 (octamer) and RNP 2 (hexamer), is 
the most widespread and well characterized RNA-binding domain. Short consensus of RRM is 
composed of about 80 amino acids, with a PafiPafi topology. RNP1 and RNP 2 are juxtaposed 
in the middle two strands of four stranded antiparallel /? sheet surface and are responsible for 
RNA recognition (Varani and Nagai, 1998). The KH (hnRNP K homology) motif is almost 70 
amino acids in length having fiaafipa topology (Adinolfi et al, 1999; Grishin 2001). The KH 
consensus sequence comes in direct contact with nucleic acids (Lewis et al 2000).
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ZBP1, the chicken ortholog of CRD-BP, has been shown to mainly reside in the cytoplasm 
and makes complexes with its mRNA target (Farina et al, 2003; Stohr et al, 2006; Huttelmaier et 
al, 2005). Earlier reports suggested a zipcode recognition sequence (ACACCC) which was found 
within the fi-actin mRNA where ZBP1 binds to (Farina et al, 2003). However, it is now clear that 
CRD-BP binding occurs with other RNA targets without the zipcode, suggesting that there is no 
specific RNA recognition sequence. Recently, crystallization studies of the third and fourth KH 
didomain of CRD-BP showed dimerization of the two KH domains with canonical RNA-binding 
surfaces exposed at opposite ends of the molecule (Chao et al, 2010).
1.5.2 mRNA targets of CRD-BP and role in cancer
CRD-BP, also known as insulin-like growth factor-II mRNA binding protein 1 (IGF2BP1 or 
IMP-1) and zipcode-binding protein 1 (ZBP1), was first described in Dr. Jeffrey Ross’ lab for its 
ability to bind the c-myc mRNA coding region determinant (CRD) and shield the transcript from 
degradation (Prokipcak et al, 1994). CRD-BP is absent or present in extremely low levels in 
normal adult tissues (Leeds et al, 1997). However, it is abundantly expressed in fetal tissues and 
in several types of human cancers, including breast, colon, skin, ovary, lung, brain, testicular, 
and chorion cancers (Doyle et al, 2000; Ioannidis et al, 2003; Dimitriadis et al, 2007; Ross et al, 
2001; Kobel et al, 2007; Kato et al, 2007; Hammer et al, 2005; Ioannidis et al, 2005; Elcheva et 
al, 2008; Ioannidis et al, 2004; Mongroo et al, 2011; Hsieh et al, 2013). Conversely, Gu et al 
(2009) reported overexpression of ZBP1 during embryogenesis and tumor formation but its 
repression in metastatic breast cancer cell lines and tumors.
In several types of cancers, CRD-BP expression correlated with poor disease outcome and 
reduced overall survival (Dimitriadis et al, 2007; Kato et al, 2007; Kobel et al, 2007; Gu, 2004). 
CRD-BP is involved in the control of cell proliferation (Ioannidis et al, 2005; Noubissi et al, 
2006; Weidensdorfer et al, 2009) as well as cell adhesion and invadopodia formation, suggesting
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its role in increasing the metastatic potential of tumour cells (Vikesaa et al, 2006). In human 
colorectal cancer cells, over-expression of CRD-BP stabilizes fiTrCPl mRNA and elevates 
pTrCPl levels, resulting in a phenotype favoring tumor development (Noubissi et al, 2006). 
These findings suggest an oncogenic role of CRD-BP.
CRD-BP binds to a number of mRNAs implicated in cancer. These include mRNAs for c-myc, 
CD44, /STrCPl, IGF-II, MITF, K-ras, GUI, and MDRl (Ioannidis et al, 2005; Sparanese and 
Lee, 2007;Vikesaa et al, 2006; Noubissi et al, 2006; Gu et al, 2008; Leeds et al, 1997; Mongroo 
et al, 2011; Noubissi et al, 2009; Goswami et al, 2010; Boyerinas et al, 2011). In many cases,
Fig 5. Schematic representation of IMP-1 action in stabilizing messenger RNAs important in 
cancer (Lily et al, 2013).
RNA binding leads to stabilization of the transcripts and an increase in their corresponding 
protein levels; the result is manifested in downstream effects and cancer phenotype (Vikesaa et 
al, 2006; Noubissi et al, 2006; Noubissi et al, 2009; Boyerinas et al, 2011).
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1.6 Three selected mRNA targets of CRD-BP
As described above that CRD-BP binds to a number of different mRNAs. In this work, I will 
mainly focus on the following three mRNAs: MDRl, GUI and CD44 mRNAs
1.6.1 MDRl
Chemotherapy is one of the most frequently used treatments for human cancer. In ovarian 
cancer, surgical de-bulking followed by a combination therapy involving paclitaxel, carboplatin 
is the first line of treatment. Its response rate is up to 80% (Yap et al, 2009). The majority of 
patients relapse within 18 months of treatment and become more resistant to chemotherapy. 
Various mechanisms lead to chemotherapy resistance, including up-regulation of members of 
adenosine triphosphate binding cassette transporters (ABC transporter family) that pump drug 
across cell membrane to extracellular space. A very common member of this family is the Multi­
drug Resistance 1 or MDRl (Ambudkar et al, 2003) which encodes for P-glycoprotein. MDRl 
substrates include toxins and commonly used therapeutic agents such as Taxanes and 
anthracyclines (Zhou, 2008).
As discussed earlier, CRD-BP was initially discovered due to its ability to bind to c-myc 
CRD RNA. Later on, it was shown that CRD-BP has similar affinity for MDRl RNA having Kd 
value of about 500 nM (Sparanese and Lee, 2007). CRD-BP binds to MDRl RNA nts 746-962 
and is capable of blocking MDRl RNA cleavage by a specific mammalian endoribonuclease in a 
concentration dependent manner (Sparanese and Lee, 2007).
1.6.2 GLI1
Wnt and hedgehog (Hh) are critical pathways involved in embryonic development, stem cell 
maintenance and tumorigenesis. Hh pathway is controlled by the Ci/GLI family of zinc finger 
transcription factors.
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Fig 6. Hh signaling pathway (a) Hh pathway inactive form: In the absence of Hh ligand, 
PTCH localizes in the cilia and represses SMO activity by preventing its trafficking and 
localization to the cilia. Translation of Hh targeted genes are inhibited (b) Hh pathway active 
form: On ligand binding, PTCH activates SMO. Activation of SMO results in translocation of an 
activated form of GLI (GLIA) to the nucleus, where it induces expression of Hh target genes. 
(Dereck et al; 2013)
In vertebrates, three different genes of GLI have been reported. Amongst them, GLI1 is a 
transcriptional activator, while GLI2 and GLI3 are both considered as activators and repressors 
(Wicking, 1999). Wnt//? catenin induces the expression of CRD-BP (Noubissi et al, 2006). 
Overexpression of CRD-BP in turn leads to drastic increase in the half-life of GLI mRNA. As an 
RNA-binding protein, it was postulated that CRD-BP binds to and stabilizes GLI1 mRNA. 
Indeed, CRD-BP was shown to have high affinity for GLU mRNA at nucleotides 41-990. 
(Noubissi et al, 2009). Expression and transcriptional activity of GLI1 by Wnt//? catenin 
signalling depends on CRD-BP, so it is thought that GLF s contribution to colorectal cancer 
formation is mainly due to its regulation by Wnt//? catenin via mRNA stability controlled by the 
physical association with CRD-BP (Noubissi et al, 2009).
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1.6.3 CD44
CD44 is a member of a large family of cell adhesion molecules responsible for adhesion 
between adjacent cells. In addition to its role in cellular adhesion, CD44 plays an important role 
in growth and motility of cells, and thus it is involved in many types of cancers, including breast, 
lung, prostate, ovarian, cervical, and colorectal cancers (Naor et al, 2002).
It has been reported that CRD-BP binds to the 3'-UTR of CD44 transcript and increases CD44 
mRNA stability. (Kobel et al. 2007; Noubissi et al. 2006; Vikesaa et al. 2006), leading to 
cytoplasmic spreading and invadopodia formation (Vikessa et al, 2006).
1.7 Oligonucleotides and antibiotics/small molecules capable of breaking RNA-protein 
interaction
The expression of genes often depends on formation of complexes between proteins and 
RNAs. As a result, gene expression can be prevented by targeting this complex. Inhibiting the 
formation of complex between protein and RNA can be a very useful approach in inhibiting gene 
expression. While many inhibition of gene expression approaches target RNA, only a few target 
protein.
RNA interference (RNAi) is a ubiquitous mechanism that reduces gene expression within 
cells. In the RNAi mechanism, single-stranded small interfering RNAs (siRNAs), generated from 
double-stranded RNAs, bind to complementary sequences on target mRNA transcripts and 
recruit RISC (RNA-induced silencing complex) to degrade the corresponding target mRNAs 
(Dykxhoom, 2006). This is an extremely useful mechanism when it comes to inhibiting gene 
expression in cells.
Antisense oligodeoxynucleotide (ODN) is another class of nucleic acid-based therapeutic agent 
that act via the activity of RNase H (Crooke, 1993). Interestingly, sequence specific ODNs have
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also been explored for use to occlude binding of CRD-BP to c-myc mRNA as an approach to 
inhibit c-myc gene expression (Coulis et al, 2000).
Aminoglycoside antibiotics, such as neomycin B, is capable of breaking protein-RNA 
Interactions (Zapp et al, 1993). During early HIV infection, the small accessory protein Rev 
binds to the Rev Response Element (RRE) of mRNAs, resulting in mRNA protection and 
localization into cytoplasm where it is translated (Van Ryk et al, 1999). Neomycin inhibits the 
binding of Rev to the RRE, thus preventing mRNA localization (Van Ryk and Venkatesan, 
1999).
A recent attempt to use small molecules as specific inhibitors of IMP 1-c-myc interaction has 
been successful. Small molecules were screened in-vitro using high throughput screening assay. 
One small molecule was successfully identified against IMP-1 positive IGROV-1 ovarian cancer 
cell line for its ability to inhibit growth. (Lily et al, 2013).
Previous researchers in Dr. Lee’s lab have successfully identified specific oligonucleotides 
that disrupt the CRD-BP-CD44 RNA interactions in vitro and specifically destabilize CD44 
mRNA in cells (King et al, 2014).
1.8 Goal of research
The general goals of this MSc thesis were two-fold. Firstly, to develop a better basic 
understanding of the molecular interaction between CRD-BP and its three targets, CD44, MDR1 
and GUI mRNAs. Secondly, with the scientific knowledge generated, to design, develop and 
test specific oligonucleotides for their ability to inhibit specific gene expression through the 
mechanism of blocking specific CRD-BP-mRNA interaction.
To achieve the general goals described above, the specific goals of my thesis were four-fold: 
(i) to develop a fluorescence-based method in an effort to rapidly study and characterize the 
CRD-BP-RNA interaction; (ii) to use electrophoretic mobility shift assays (EMSAs) to study
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CRD-BP-GL/7 and -MDR1 RNA interaction; (iii) to use electrophoretic mobility shift assays to 
study and to compare the WT CRD-BP and its various KH variants for binding to GUI and 
CD44 RNAs; and (iv) to assess specific RNA oligonucleotides for their ability to disrupt the 
CRD-BP-GL/7 RNA interaction in vitro and destabilize GUI mRNA in cells.
To achieve the first specific goal, I first aimed to develop the fluorescence EMSA which would 
allow me to quantify CRD-BP-RNA interaction. To achieve the second specific goal, I used 
EMSA to map the smallest RNA regions of GLI1 and MDR1 which bind CRD-BP. To 
accomplish the third specific goal, I used EMSA to compare and contrast the wild-type CRD-BP 
with a panel of KH variants of CRD-BP for their ability to bind GLI1 and CD44 RNAs. Finally, 
to accomplish the fourth specific goal, I used EMSA to assess specific RNA oligonucleotides for 
their ability to compete with GUI RNA for binding to CRD-BP. The 2’-0-methyl version of the 
oligonucleotides were then assessed for their ability to specifically destabilize GLll mRNA in 
cells as determined using quantitative real-time PCR.
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Generation and purification of the recombinant wild type CRD-BP (WT-CRD-BP) and its 
binding ability with truncated RNA fragments of GUI and MDRl RNAs in-vitro, using 
electrophoretic mobility shift assay (EMSA) will be discussed in this chapter. Designing of 
specific oligonucleotides and their ability to compete with GUI RNA for binding to the WT- 
CRD-BP will also be discussed in this chapter.
One of the main goals was to map the smallest possible regions of these two RNAs which are 
still capable of binding to the WT-CRD-BP. RNA or DNA oligonucleotides that could break 
GUI RNA-CRD-BP interaction was designed. This chapter is divided into the following 
three parts.
(A) Assessing CRD-BP-RNA interaction using fluorescently labelled MDRl 
RNA
(B) Assessing CRD-BP-RNA interaction using [32P] radio labelled MDRl and GUI 
RNAs
(C) Breaking CRD-BP-GUI RNA interaction
Part A: Assessing CRD-BP-RNA interaction using fluorescently labelled MDRl 
RNA
In this section, I explored the possibility of using fluorescent EMSA technique to study CRD- 
BP-RNA interaction in-vitro.
1.2.1. Methodology:
1.2.1.1. Generation and Purification of the Coding Region Determinant-Binding 
Protein
The wild type CRD-BP was generated and purified using the following methods.
1.2.1.2. Transformation of competent E.coli BL21 cells
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Approximately 100 ng of purified pet28B-WT-CRD-BP plasmid was added to 100 pL of 
thawed BL21 cells, followed by incubation on ice for 25 minutes. The transformation mixture 
was heat shocked for 90 seconds at 42°C and placed on ice for 1 minute. After addition of LB- 
broth (-300 pL), the mixture was incubated at 37°C for 30 minutes. After incubation, the cells 
were plated onto LB-Kanamycin plates and placed in incubator at 37°C overnight (-16 hours) to 
give sufficient time for colony formation.
1.2.1.3. Cell Growth and Induction
Following the overnight incubation, about 20 bacterial colonies were picked from the plate and 
inoculated in 100 mL of LB-Kanamycin broth in a 250 mL flask and transferred to bacterial 
shaker to grow (200 rpm, 37°C) for -3  hours. The 100 mL of bacterial culture was transferred to 
900 mL of LB-Kanamycin broth in a 3 L flask. The flask was placed back in the same shaker 
until an OD600 = 0.5 was reached (-2-3 hours). After achieving the desired OD600 = 0.5, 1 mL 
1 M IPTG was added to induce recombinant protein production. The Flask was left for a 6-hour 
growth period in the shaker, the bacterial cultures were spun down (3000 x g, 4 °C, 15 minutes) 
and the bacterial pellet was kept at -80°C overnight.
1.2.1.4. CRD-BP purification under denaturing conditions
The next morning, bacterial pellets were thawed on ice for 15 minutes. Once thawed, the pellet 
was resuspended in 12 mL of Buffer B (100 mM NaH2 PC>4 , 10 mM Tris-Cl, 8 M Urea, adjusted 
to pH 8) and transferred to a 50 mL falcon tube. The solution was then gently agitated on shaker 
at 4°C until the solution turned semi-translucent (-60 minutes). In the meantime, the pH of the 
remaining buffers was adjusted using the stock Buffer B (C-pH 6.5, D-pH 6.3, and E-pH 5.9). 
The bacterial solution was then spun down (13,200 rpm, 4°C, and 30 minutes) and the 
supernatant was collected. The supernatant was then loaded onto a Nickel-NTA gravity drip 
column (column was equilibrated with Buffer B). Each buffer was passed over the supernatant
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loaded on the column one by one. CRD-BP was expected to elute in buffer E. Fractions were 
collected and then checked for protein purity using Coomasie blue-stained SDS-PAGE. Briefly, 
16 pL samples from different fractions was mixed with 4 pL 5 x Sample buffer and 1 pL of P- 
mercaptoethanol and then boiled for 5 minutes. Samples were then loaded on to a 12% SDS- 
PAGE gel; 19:1 acrylamide:N,M-methylenebisacrylamide and resolved at 120 V for -35 
minutes. E fraction proteins were used in all subsequent experiments due to high protein purity.
1.2.1.5. Protein Dialysis
All purified proteins were dialysed using a two-step gradient to remove urea from the Buffer E 
elution buffer and to help protein renaturation. Approximately 100 pL of the purified protein was 
added into each Slide-A-Lyzer mini dialysis unit (Pierce, Rockland IL, USA) and the unit was 
placed in a 100 mL beaker containing 50 mL of dialysis buffer A (1 M Tris-Cl, 0.2 M 
glutathione-reduced, 0.1 M glutathione-oxidized, 1.33 M glycerol, 2 M urea, 0.0001% Triton-X, 
adjusted to pH 7.4). Buffer exchange was allowed for 24 hours. After 24 hours, the dialysis units 
were transferred to 250 mL beaker containing 50 mL of dialysis buffer B (1 M Tris-Cl, 1.33 M 
glycerol, 0.0001% Triton-X, adjusted to pH 7.4). After 2 hours, dialysis units were transferred to 
250 mL beaker containing 200 mL of buffer B for 2 more hours. Dialysed protein was spun 
down at 13,200 rpm for 30 minutes to remove any aggregation. Following protein dialysis, the 
concentration of the protein was determined using Quick Start ™ Bradford lx Dye Reagent 
(BioRad, Catalog Number 500-0205). The dialyzed proteins were then used for EMSA within 3 
weeks upon dialysis.
1.2.1.6. Generation of DNA template for in-vitro transcription
Polymerase chain reaction (PCR) was employed to generate truncated MDRl and GLI1 DNA 
templates using MDRl cDNA (accession # M l4758) and GUI cDNA (accession # 013000) 
respectively. The different sets of forward and reverse primers used to amplify the different
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regions of GLI1 cDNA are shown in Table 1. Forward and reverse primers used to amplify 
MDRl cDNA are shown in Table 3.
Table 1. Primer sequences for amplifying fragments of GLI1 cDNA.
Fragments Primers
G L I36-231 Forward:
GGATCCTAATACGACTCACTATAGGGCCATGTTCAACTCGAT
G
Reverse: CCTCGGTGCAGCTGTTGG
GLI 230-420 Forward:
GGATCCTAATACGACTCACTATAGGGGGCCCACTCTTTTCTTC 
Reverse: TGCCAATGGAGAGATGAC
GLI 420-610 Forward:
GGATCCT AAT ACGACTC ACT AT AGGACC ATGAGCCCATCTCT 
G
Reverse: CGGCACTTGCCAACCAGC
GLI 610-800 Forward:
GGATCCTAATACGACTCACTATAGGGGGAGGAACCCTTGGAA
G
Reverse: GTGCACCAGCTGCTCTTG
GLI 800-990 Forward:
GGATCCT AATACGACTCACTATAGGCCACATCAACAGCGAGC 
A
Reverse: GGTTTTCGAGGCGTGAGT
GLI 230-380 Reverse: GCATCGCGAGTTGATGAA
GLI 230-330 Reverse: CCGTCTGCAGGTCCAGGC
GLI 230-300 Reverse: GAGGTGAGATGGACAGTG
GLI 230-275 Reverse: CTTGGTCAACTTGACTGC
GLI 270-420 Forward:
GGATCCTAATACGACTCACTATAGGACCAAGAAGCGGGCACT 
G
GLI 320-420 Forward:
GGATCCT AAT ACGACTC ACT AT AGGCCTGCAGACGGTT ATCC 
G
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GLI 350-420 Forward:
GGATCCT AATACG ACT C ACT AT AGGCTCCCT CGT AGCTTT CAT
GLI 375-420 Forward:
GGATCCTAATACGACTCACTATAGGCGATGCACATCTCCAGG
______________ A___________________________________________________________
All forward primers have T7 promoter sequence at the 5’end (underlined)
Reaction tubes were set up as in Table 2. PCR reactions were performed in a thermo cycler 
using the following program- 94°C- 30 seconds, 50°C- 30 seconds, 72°C - 45 seconds for 35 
cycles.
Table 2. Reagent used in PCR to synthesize DNA template
Reagent Amount
DNA template 100 ng
lOxPCR buffer 3.5 pL
dNTPs (2.5mM) 3.5 pL
Forward primer with T7 promoter (lOOng/ pi) 1 pL
Reverse primer lOOng/pl 1 pL
Taq polymerase (NEB) 0.5 pL
H20 24.5 pL
Total Volume 35 pL
PCR products were resolved on a 2% or 2.5 % agarose gel depending upon the sizes of DNA. 
The PCR products were subjected to standard ethanol precipitation (2.5 x volume ethanol, 1/10 
volume sodium acetate (3 M, pH 5.2 in lOx glycogen). Concentration of DNA was determined 
using Nanodrop Spectrometer (NanoDrop technologies). Impure DNA templates were gel 
extracted using Qiagen QIAEX®II gel extraction kit.
31
Chapter 2. Characterizing the physical interaction between CRD-BP and its two mRNA targets,
MDRl and GUI
A
36 990 3’
36 ........................  231
230 — —  420
420 ■— — —  610
610 — — —  800
800 990
B
230 42Q 3>
230 380
230 330
230 — i 300
230      275
270 ^ ■“ ■■■■■■■■ 420
320 420
350 420
375              —  420
Fig 7. Schematic diagram of truncated G U I  cDNA template. (A) Strategy to make five 
truncated G UI cDNA spanning nts 36-990, each having ~190 nts using different sets of forward 
and reverse primers. (B) Strategy to make 3’ and 5’ truncated G UI cDNA spanning nts 230-420 
each having different sizes.
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Fig 8. Schematic diagram of truncated M D Rl cDNA template. Strategy to make 3’ and 
5’truncated MDRl cDNA spanning nts 739-921 using different sets of forward and reverse 
primers.
Table 3. Primer sequneces for amplifying fragments of M DRl cDNA.
Fragments Primers
MDR 739-921 Forward:
GG AT CCT AAT ACG ACT C ACT AT AGG AAT CTGG AGG AAG AC AT 
G
Reverse: TGCACATCAAACCAGCCT
MDR 739-881 Reverse: GAAAAAACTGTTTTCTAA
MDR 739-845 Reverse: CAGCTGCCAGGCACCAAA
MDR 739-815 Reverse: TGTAAGCAGCAACCAGCA
MDR 739-785 Reverse: TTCCACTGTAATAATAGG
MDR 779-881 Forward:
GGATCCTAATACGACTCACTATAGGAGTGGAATTGGTGCTGG 
G
MDR 819-881 Forward:
GGATCCTAATACGACTCACTATAGGAGGTTTCATTTT
GGTGCC
MDR 850-881 Forward:
GGATCCTAATACGACTCACTATAGGACAAATACACAAAATTA
G
All forward primers have T7 promoter sequence at the 5’ end (underlined)
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1.2.1.7. Internal labeling of RNA oligonucleotide using Fluorescein-UTP
In order to generate good quality fluorescently labeled RNA substrate, fluorescein-labeled UTP 
was used to internally label the RNA substrate using MAXIscript® kit (Invitrogen). Reagents 
from the kit (Nuclease free H2O, 10 x buffer, 10 mM NTPs, FI-UTP, 1 U T7 polymerase) and 1 
pg DNA template were used in each reaction. Reaction mixture was incubated at 37°C for 60 
minutes. Following incubation, DNase I was added to degrade DNA template and reaction 
mixture was again incubated at 37°C for 15 minutes. After DNase treatment, 0.5 M EDTA was 
added to the reaction mixture. Standard phenolichloroform extraction was then performed to 
remove any residual proteins from the reaction. The RNA was ethanol precipitated as described 
above and column purified using G-50 column to remove unincorporated nucleotides.
1.2.1.8. Fluorescent electrophoretic mobility shift assays
To assess the binding ability of WT-CRD-BP to fluorescently labeled RNA substrate, 
electrophoretic mobility shift assay (EMSA) was performed. EMSA binding buffer (Table 5) 
was made fresh for each experiment and was placed on ice prior to use. Fluorescently labeled 
RNA substrates were subjected to a denaturation and renaturation steps that involved heating the 
RNA to 55°C for 5 minutes and then cooling at room temperature for 7 minutes. EMSA reaction 
tubes (binding buffer, BSA, yeast tRNA, RNasin, RNA, protein) were then incubated at 37°C for 
10 minutes. Following incubation, tubes were placed on ice for 5 minutes. This heating cooling 
cycle to facilitate binding was repeated, for a total of two times. EMSA loading dye (2 pL) was 
then added to the reaction and 15 pL of the reaction was loaded on to an 8% native 
polyacrylamide gel. Complexes were resolved at 25 mA for 90 minutes. The gels were then 
visualized using the Kodak Image Station 4000MM PRO.
1.2.2. Results
1.2.2.1. Generation of DNA templates
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Eight MDRl and thirteen GLIl truncated DNA templates were synthesized using specific 
reverse and forward primers (with T7 promoter). PCR was performed as described above. PCR 
products were resolved on agarose gels to confirm product size and purity. As shown in Figs. 9- 
10, most of the amplified DNA templates were pure and of the expected size.
A
Fig 9. Agarose gel analysis of PCR generated G LIl cDNA templates. (A) Five truncated 
GLIl cDNA template having -190 nts were resolved on 2% agarose gel. (B) 3’ truncated GLIl 
cDNA templates were resolved on 2.5% agarose gel. (C) 5’ truncated GLIl cDNA templates 
were resolved on 2.5% agarose gel.
35
Chapter 2. Characterizing the physical interaction between CRD-BP and its two mRNA targets,
MDRl and GLIl
A
B
506 — I  
396— 1 
344- 
298 -
201,220—|
154— I 
134— I
75— 1
Fig 10. Agarose gel analysis of PCR generated M DRl cDNA templates. (A) 3’ truncated 
MDRl cDNA templates were resolved on 2.5% agarose gel. (B) 5’ truncated MDRl cDNA 
templates.
I.2.2.2. Purification of WT-CRD-BP
To confirm that the IPTG-induced purified WT-CRD-BP protein is pure, protein fractions
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A
Fig 11. SDS-PAGE analysis of recombinant WT-CRD-BP. To confirm generation and 
purification of CRD-BP. Various B-F fractions (A and B) were analyzed on 12% SDS-PAGE. 
Gels were stained with Coomassie blue stain.
eluted at different pH were run on a 12% SDS-PAGE. As shown in Fig 11, an intense band of 
about 68 kDa which eventually became the only dominant band at the later E-fractions and in F
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fraction was observed. This band has been previously confirmed to be recombinant CRD-BP 
using anti-CRD-BP and anti-FLAG antibodies (Barnes et al, submitted,); Sparanese and Lee, 
2007).
I.2.2.3. Generation of fluorescently labelled MDRl RNA
Internal labelling of fluorescent RNA was performed using fluorescein UTP and 
MAXIscript® kit (Invitrogen). As shown in Fig 12, both the fluorescently labeled MDRl and c- 
myc RNAs were successfully generated. The MDRl RNA is expected to be 183 nts and the c- 
myc is expected to be 182 nts, therefore the approximate similar size of both transcripts 
supported the identity of the bands.
Fig 12. Analysis of in-vitro transcription product. MDRl and c-myc transcripts resolved on a 
8% denaturing polyacrylamide gel.
I.2.2.4. Fluorescent EMSA
After successfully obtaining fluorescent labeled MDRl RNA, electrophoretic mobility gel shift
assay was performed using different concentrations of CRD-BP (Fig 13). A faint band of higher
molecular weight which was absent in the lane with no CRD-BP added, was observable in lanes
containing CRD-BP. Unfortunately, the CRD-BP-RNA complex band remained faint based on
multiple experiments and could not be feasibly used for quantification purposes. Therefore, the
fluorescent EMSA was deemed inappropriate for further use. For the remaining work, the
radioactive EMSA using [32P]-labeled RNA was employed to study CRD-BP-RNA binding.
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Fig 13. Fluorescent EMSA of M DRl nts 739-921. EMSA binding reaction was performed 
using MDRl and various concentration of WT-CRD-BP. Formation of protein-RNA complex 
indicates that MDRl RNA binds with CRD-BP.
Part B: Assessing CRD-BP-RNA interaction using [32P] radiolabelled M DRl and GLFl 
RNA
After the unsuccessful attempt in using the fluorescent EMSA to quantify CRD-BP-RNA 
interaction, an alternate method was chosen to assess CRD-BP-RNA interaction. I decided to use 
the radioactive EMSA to study and quantify CRD-BP-RNA interaction.
II.2.1. Methodology
II.2.1.1. Generation of internally [32P] labeled RNA substrate
Radio-isotope [32P-UTP] labeled MDRl and GLIl RNA substrates were generated via in-vitro 
transcription using linearized DNA template as prepared above. T7 directed in-vitro transcription 
was performed to synthesize RNA of desired size. The required reagents given in Table 4 were 
mixed in reaction tube and incubated at 37°C for 1 hour. DNase I was added to destroy DNA 
template and reaction was incubated again at 37°C for 15 minutes. RNA stop dye was added to 
the reaction mixture and mixture was loaded onto an 8% denaturing PAGE gel. Reaction mixture 
was resolved for 60 minutes at 25 mA. Gel was visualized using Cyclone Storage Phosphor 
Screen System and Optiquant Software. Gel extraction of the desired product was performed.
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Gel homogenate was loaded on a DTR column and spun at 3000 rpm for 3 minutes to remove gel 
fragments and free nucleotides. Standard phenol:chloroform extraction was then used to remove 
any possible residual proteins. Ethanol precipitation was then carried out to concentrate the RNA 
substrate. The radioactivity of the substrate was checked using a scintillation counter. The RNA 
substrates were then diluted and subsequent binding reactions used ~40,000 - 50,000 cpm 
(counts per minutes) per reaction.
Table 4. Reagents used in generation of [32P] labelled RNA
Reagent Amount
DNA template with T7 promoter(l pg/pL) 1 pL
5* transcription buffer 4 pL
100 mM DTT 2 pL
RNasin 20 U/pL 1 pL
10 mM ATP 1 pL
10 mM CTP 1 pL
10 mM GTP 1 pL
100 pM UTP 2.5 pL
32P -UTP 3 pL
T7 RNA polymerase 15 U/ pL 1 pL
DEPC water 2.5 pL
Total 20 pL
II.2.1.2. Radioactive electrophoretic mobility shift assay
To assess the ability of CRD-BP to bind [32P]-labeled MDRl and GLIl RNA substrates, 
radioactive electrophoretic mobility shift assays (EMSA) were performed. EMSA binding buffer
32(Table 5) was made fresh at the start of each experiment and was placed on ice until used. [ P]- 
labeled RNA substrates were subjected to a denaturation and renaturation steps that include 
heating the RNA to 55°C for 5 minutes and then cooling at room temperature for 7 minutes. 
Equal amounts of binding buffer and RNA substrates, while various concentrations of CRD-BP 
were added to the EMSA reaction tubes. EMSA reactions were then incubated at 35°C for 10 
minutes, and then kept on ice for 5 minutes. This heating and cooling cycle to facilitate binding 
was performed two times. EMSA loading dye (2 pL) was then added to the reactions and 15 pL
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of the binding reaction was loaded on to a 4% native PAGE gel and resolved at 25 mA for 50-55 
minutes. Audioradiography was performed using a Cyclone Storage Phosphor Screen System 
and Optiquant Software.
Table 5. Reagents used for fluorescent and radioactive EMSA
Reagent Composition
EMSA binding buffer 5 mM Tris-Cl (pH 7.4), 2.5 mM EDTA (pH 8), 2 mM DTT, 
5% glycerol,0.1 mg/mL (BSA), 50 ug/uL Yeast tRNA 
(Invitrogen), 5U RNasin
EMSA loading dye 250 mM Tris-Cl (pH 7.4), 0.2% bromophenol blue, 0.2% 
xylene cyanol,40% sucrose
II.2.2. Results:
II.2.2.1. Mapping of GLIl RNA
All radiolabelled RNAs were gel purified and precipitated successfully. GLIl RNA substrates 
had radioactivity of about 800,000-1000,000 cpm while MDRl fragments had radioactivity of 
about 200,000-300,000 cpm. Radioactivity was measured using scintillation counter.
Radiolabelled EMSA was performed on five [32P]-labeled GLIl fragments (36-231, 230-420, 
420-610, 610-800, 800-990), each having -191 nts. Various CRD-BP concentrations were added 
to observe the binding ability of these five RNA fragments. Out of these five fragments, only one 
fragment (230-420) showed binding with CRD-BP (Fig 14A). GLI 420-610 did not show any 
binding with CRD-BP even at 1080 nM concentration of protein (Fig 14A). GLI 36-231, GLI 
610-800 and GLI 800-990 did not show binding with CRD-BP as shown in Fig 14B. At higher 
protein concentrations, the intensity of free RNA was reduced and this was most likely due to the 
aggregation of proteins in the wells of gel. Radiolabelled EMSA was also performed on eight 
other 3’ and 5’ truncated [32P]-labeled truncated fragments of GLIl nts 230-420. As shown in 
Fig. 15-16, out of these eight RNA fragments, only four fragments showed binding with WT-
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CRD-BP. Interestingly, all truncated fragments which showed binding with CRD-BP possess nts 
320-380, suggesting that this could represent a minimal region required for binding to CRD-BP.
Fig 14. Mapping the G LIl RNA nts 36-990 for ability to bind CRD-BP. All five truncated 
GLI RNA  substrates were allowed to bind with various concentrations of CRD-BP using [32P]- 
radiolabeled EMSA reaction. Reaction mixture was resolved on 4% native PAGE. (A) GLI 230- 
420 showed binding with CRD-BP while GLI 420-610 did not show any binding. (B) All three 
GLIl fragments showed no binding with CRD-BP.
A B
Fig 15. Mapping the 3’ truncated G LIl RNA nts 230-420 for ability to bind CRD-BP. All
four 3’ truncated GLI 1 RNA substrates were allowed to bind with various concentrations of 
CRD-BP using [32P]-radiolabeled EMSA reaction. Reaction mixture was resolved on 4% native 
PAGE. (A) 3’ truncated GLI 230-380 showed binding with CRD-BP while GLI 230-330 showed 
no binding. (B) 3’ truncated GLI 230-300 and GZ.7 230-275 showed no binding with CRD-BP.
A B
C-Myc GU 230-420 GLI 420-610 C-Myc GLI 610-800 GU 800-990 GU 36-231
CRD-BP (nM ) 0  ,< >  H l V /  0  0  * 1 ^ 0  ^ 1 *
Bound RNA
Free RNA
C-Myc GU 230-380 GU 230-330
C
GU 230-420 GU 230-300 GU 230-275
Bound RNA
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A
GU 230-420 GLI 270-420 GU 320-420
Bound RNA
B
GU 350-420 GU 375-420
Bound RNA
Fig 16. Mapping the 5’ truncated GLIl RNA nts 230-420 for ability to bind CRD-BP. All
four 5’ truncated GLI 1 RNA substrates were allowed to bind with various concentrations of 
CRD-BP using [32P]-radiolabeled EMSA reaction. Reaction mixture was resolved on 4% native 
PAGE. (A) 5’ truncated GLI 270-420 and GU  320-420 showed binding with CRD-BP. (B) 5’ 
truncated GLI 350-420 showed binding with CRD-BP while GLI 375-420 showed no binding.
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GLI 320-380
Bound RNA
Free RNA
Fig 17. Assessing GLIl RNA nts 320-380 nts for ability to bind CRD-BP. GLI 320-380 RNA 
substrate was allowed to bind with various CRD-BP concentrations using [32P]-radiolabeled 
EMSA reaction. Reaction mixture was resolved on 4% native PAGE.
After performing EMSA, it was evident that GLI 320-380 region plays an important role in 
binding CRD-BP. Next, the MFOLD web server was used to generate predicted secondary 
structure of GLIl 301-380. The MFOLD generated predicted secondary structure of GLIl nts 
301-380 is shown in Fig 18A. This structure contains two stem loops within 346-382 nts region 
as shown in Fig 18A. Interestingly, the 2862-2930 nts CD44 RNA which is also capable of 
binding CRD-BP also contains the two stem loops as shown in Fig 18B. This 69 nts CD44 RNA 
was also capable of binding CRD-BP (King et al, 2014).
A B
Fig 18. MFOLD (Zuker, 2003) generated secondary structures of (A) GLI RNA nts 301-380 
and (B) CD44 RNA nts 2862-2930
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11.2.2.2. Mapping of MDRl RNA
Radiolabelled EMSA was also performed on [32P]-labeled truncated MDRl RNA. The MDRl 
RNA nts 739-921 has been previously shown to bind CRD-BP (Sparanese and Lee, 2007).
A
MDR1 739-921 MDR1 739-845 MDR1 739-815 MDR1 739-785
Bound RNA
B
MDR 739-921 MDR 779-881 MDR 819-881 MDR 850-881
Bound RNA
Free RNA
9  qg»C>.hT-g> O  v s O
Bound RNA
Free RNA
MDR 739-921 MDR 739-881
9  n& epP
Fig 19. Mapping of MDRl RNA for ability to bind CRD-BP: 3’ and 5’ truncated MDRl 
RNAs were incubated with various concentrations of CRD-BP and reaction mixture was 
resolved on 4% native PAGE. (A) MDR 739-845 and MDR 739-815 showed binding with 
protein while MDR 739-785 showed no binding. (B) MDR 779-881 and MDR 819-881 showed 
binding with protein while MDR 850-881 showed no binding. (C) MDR 739-881 shows binding 
with CRD-BP.
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Out of seven 3’ and 5’ truncated MDRl RNAs, three RNAs nts 739-881, 739-845 and 779-881 
showed high affinity for CRD-BP (Fig 19). MDRl RNA nts 739-815 and 819-881 RNAs showed 
weak binding while nts739-785 showed very weak binding (Fig 19). In contrast, nts 850-881 
RNAs showed no binding with CRD-BP. MDRl RNA nts 779-881 appeared to have similar 
affinity as the RNA nts 739-921 for CRD-BP (Fig 19), suggesting that nts 779-881 of MDRl 
RNA plays important role in binding to CRD-BP.
Part C: Breaking CRD-BP-GL/7 RNA interaction
After mapping the smallest region of GLIl RNA which can bind CRD-BP, my next goal was to 
design and assess specific oligonucleotides for ability to disrupt CRD-BP-GL/1 RNA interaction 
in vitro. This section discusses the design of specific RNA and DNA oligonucleotides and the 
experiments conducted to assess the ability of these oligonucleotides to compete with the [ P]- 
labeled GLIl nts 230-420 for binding to CRD-BP.
III.2.1. Methodology
m.2.1.1. Designing RNA and DNA oligonucleotides using MFOLD
The predicted secondary structure of GLIl RNA nts 301-380 containing the two stem loops in 
region 346-382 nts is shown in Fig 20 .1 hypothesize that these two stem loops play an important 
role in binding CRD-BP. To test the hypothesis that the secondary structure, particularly the 
two stem loops, as well as sequence of GLIl RNA are critical in binding CRD-BP, eight RNAs 
and one DNA oligonucleotides were designed using MFOLD as shown in Fig 21. These 
oligonucleotides with identical length were designed to have different structures as well as slight 
variations in their nucleotide sequences as shown in Table 6. DNA oligonucleotide and SI have 
exactly the same structure and nucleotide sequences as GLI 346-382 nts region. S2, S3, S4, S5 
and S6 were designed to test the importance of both loops to bind CRD-BP. S7 was designed to
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observe the importance of both stems in binding CRD-BP, while S8 was designed to test the 
importance of stem structure to bind CRD-BP.
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Fig 20. MFOLD generated predicted secondary structure of GLIl RNA nts 346-382
Table 6. Sequences of the designed DNA and RNA oligonucleotides
Oligonucleotides Sequence (5’ to 3’)
DNA oligonucleotide CCAGCTCCCT CGTAGCTTTC ATCAACTCGCGATGCAC
SI CCAGCUCCCUCGUAGCUUUCAUCAACUCGCGAUGCAC
S2 CCGGACCCCUCGUAGCUUUCAUCAACUCGCGAUGCAC
S3 CCAGCUCCCUCGUAGCUUUCAUCAACUCGCCACCCCC
S4 CCAGCUCCCUAGCUUUUUUCAUCAACUCGCGAUGCAC
S5 CCAGCUCCCUCGUAGCUUUCAUCAACUGAUGCACCCG
S6 CCCCCAGCUCCCUAGCUUUCAUCAACUCGCGAUGCAC
S7 CCCUGCCCCUCGUGCAGUUUCUAAACUCGCUAGACAC
S8 CCAGCUGAACGAAAGCUUUCAUCUUAACCCGAUGCAC
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DNA oligonucleotide
S3 S4 S5
Fig 21. The predicted secondary structures of DNA oligonucleotide and RNA 
oligonucleotides (S1-S8) as generated by MFOLD.
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IU.2.1.2. Generation of [32P]-labelled GLI230-420
[32P]-labeled G U  230-420 RNA substrate was synthesized as described above
IH.2.1.3. Generation of unlabelled RNA
Unlabelled GUI RNA nts 230-420, 420-610 and 320-380 were synthesized using T7 
polymerase directed in-vitro transcription. Each reaction was set up as according to the quantities 
given in Table 7. Reaction was incubated at 37°C overnight. Reaction mixture was treated with 
DNase I to remove the DNA template. Phenol-chloroform extraction was done to remove protein 
impurities followed by passing through G50 column to remove unincorporated nucleotides. RNA 
was ethanol precipitated and suspended in DEPC water. Purity of the product was checked by 
running the product on 2.5% agarose gel. Concentration of RNA was determined using 
Nanodrop spectrometer (NanoDrop Technologies).
Table 7. Reagents used in synthesis of unlabelled RNA
Reagent Amount
Gel Purified DNA template (lug/pL) 5 pL
10 x T7 buffer (w / Triton X) 10 pL
100 mM ATP 5 pL
100 mM CTP 5 pL
100 mM GTP 5 pL
lOOmMUTP 5 pL
RNasin (40 U/pL) 1 pL
T7 polymerase 5 pL
dH20 57 pL
Total 100 pL
III.2.1.4. Competition assay with oligonucleotides
[32P]-labelled GLI\ RNA nts 230-420 was synthesized as mentioned above. CRD-BP protein 
was purified, dialysed and quantified as mentioned above. Competition assay was optimized by 
adding 13 nM [32P]-labelled G U  230-420 with 300 nM CRD-BP and 1/6-.1/3-, 1-, 1.5- and 10- 
fold molar excess increased in unlabelled GU  230-420 and GU  420-610.
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EMSA competition assay was performed between [32P]-labelled G L I230-420 RNA with the 
designed oligonucleotides as well as unlabelled GLI 320-380. The final concentration of 13 nM 
G U  230-420 and 300 nM CRD-BP were used. For the unlabelled GLI 320-380, 246- and 1723- 
fold molar excess , while 1615-, 4846-, 8075-, 11305-fold molar excess were used. Reaction 
mixture was incubated at 35°C for 10 minutes before putting on ice for 5 minutes. This heating 
cooling cycle was done for a total of two times. Two pL EMSA loading dye was added in each 
tube and reaction was loaded onto 4% non-denaturing polyacrylamide gel. Reaction mixture was 
resolved for 55 minutes at 25 mA. Audioradiography was performed using a Cyclone Storage 
Phosphor Screen System and Optiquant Software.
III.2.2. Results
III.2.2.1. Optimization of competition assay
As clearly shown in Fig 22, the unlabelled GL1230-420 competed effectively with the [32P]- 
labelled GLI 230-420. At 1.5 fold molar excess, the unlabelled GLI 230-420reduced the bidning 
of [32P]-labeled GLI 230-420 to CRD-BP by 50%, while at 10-fold molar excess the binding was 
reduced to 15%. The unlabelled GLI 230-420 has the exact same sequence as of [ P]-labelled 
G U  230-420, so it is not surprising to be an effective competitor.
GLI 2 3 0 -4 2 0
Fold In c rea se  ® N
B ound RNA
Free RNA
Fig 22. Optimization of competition assay: Competition assay was optimized by adding 
different fold increase in unlabelled RNA substrate of GLI 230-420. Reduced binding was 
observed beginning at 1.0-fold concentration of unlabelled GLI 230-420.
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III.2.2.2. Competition assay with RNA and DNA oligonucleotides
Upon demonstrating the ability of the unlabeled GLI RNA nts 230-420 to compete with the 
radiolabeled version to bind to CRD-BP, different concentrations of the designed 
oligonucleotides were assessed for their ability to compete with the [3 2P]-labelled GLI 230-420 
RNA for binding to CRD-BP. As shown in Fig 23A, the in-vitro transcribed unlabelled GLI 320- 
380 RNA competed effectively with [3 2P]-labelled GLI 230-420.
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Bound RNA
Free RNA
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Fig 23. Breaking GLI 230-420-CRD-BP interaction using specific oligonucleotides.
Competition assay was performed by adding various concentrations of oligonucleotides along 
with [3 2P]-labelled GLI 230-420 and CRD-BP. Reaction mixture was resolved on 4% native 
PAGE. (A) GLI 320-380 diluted the protein-RNA complex at lower concentration. DNA oligo 
did not affect GL/-CRD-BP binding while SI completely disrupted the interaction at 11305-fold 
molar excess. (B) S2 and S3 both reduced binding. (C) S5 also affected protein-RNA binding 
while S4 showed no effect on binding. (D) S6  and S7 showed no effect on binding, while S8  
affected the binding to some extent.
51
Chapter 2. Characterizing the physical interaction between CRD-BP and its two mRNA targets, 
MDR\ and GUI
At 246-fold increase in molar concentration it reduced the binding to 26% while at 1723-fold 
increase in molar concentration it reduced binding to 13%. Oligonucleotide SI reduced binding 
to 11% at 11305-fold molar increase. S2 and S3 also showed significant reduction at 11305-fold 
molar excess and reduced binding to 60% and 44% respectively. There was no effect on binding 
after addition of various concentrations of S4, S6 , S7, and the DNA oligonucleotide as shown in 
Fig 23. At 11305-fold molar excess, S5 reduced binding to 24% while S8  reduced binding to 
84%. From multiple experiments, it is clear that SI is the best RNA competitor. SI is the sense 
oligonucleotide having the identical sequence and structure as of GLI nts 346-382. The overall 
EMSA competition results suggest that the two stem loops of GLI 230-420 RNA do indeed play 
an important role in binding to CRD-BP.
2.3 Discussion
This chapter mainly focussed on characterizing the CRD-BP-RNA (GL/1 and MDRl) 
interaction in vitro and then finding specific oligonucleotides that are capable of breaking the 
CRD-BP-GZJ/ RNA interaction. One of the best available in vitro techniques used to study 
protein-RNA interaction is EMSA. CRD-BP-RNA interaction was first assessed using 
fluorescent EMSA. Fluorescence EMSA was given the priority over radiolabeled EMSA because 
of its safety and cost effectiveness. Although internally-labeled fluorescent RNAs were 
successfully synthesized and used, unfortunately the fluorescent EMSA could not give the 
desired results which permit its regular use in studying CRD-BP-RNA interaction. Firstly, the 
sensitivity of fluorescent RNA-protein complex was too low for quantification purposes. 
Secondly, fluorescent RNA-protein aggregation in the wells of polyacrylamide gels was 
consistently observed. The presence of such complexes might be due to the presence of large 
sized and number of fluorescein molecule internally attached to the transcript. This problem was 
addressed by using different ratios of fluorescein-UTP and unlabeled UTP to reduce fluorescein
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UTP molecules in the transcript, but to no avail. Another possible problem was the non-specific 
protein aggregation. This problem was solved by using E-eluted protein fraction because F- 
eluted protein fractions tend to make aggregates (Sparanese and Lee, 2007). The dialysis 
protocol was also modified to minimize risk of protein aggregation. These latter strategies helped 
in improving the mobilization of protein-RNA complexes but as mentioned above the low 
sensitivity of protein-RNA bands did not permit quantification of band intensity for the purpose 
of calculating dissociation constant Kd values.
After multiple failed attempts in performing fluorescent EMSA, radiolabeled EMSA was the 
alternate option available. Radiolabeled EMSA was already a well-established method in the lab 
(Sparanese and Lee, 2007; King et al, 2014; Kim et al, 2011 and 2014; Barnes et al, submitted). 
The radiolabeled EMSA was successfully used in this work to study CRD-BP-RNA interaction. 
In mapping the smallest GLIl RNA that binds CRD-BP, I showed that GLI 320-380 nts region 
plays a pivotal role in CRD-BP-GZJ RNA interaction. The 61 nts GLIl nts RNA 320-380 has 
two stem loops of equal sizes. I hypothesized that both loops are important in binding to CRD- 
BP. The MDR1 RNA nts 779-881 shows strong binding with CRD-BP, suggesting that 103 nts 
region of MDR1 RNA is sufficient for binding CRD-BP. These results also confirm that strategy 
to make truncated RNA fragments is a valid and easy approach to map the region of any RNA 
that binds CRD-BP.
Specific oligonucleotides were designed to test the hypothesis that the secondary structure stem 
loops and its sequences are important for binding CRD-BP. SI RNA oligonucleotide has the 
same sequence and structure as the GLIl RNA nts 346-382 and was the most effective 
competitor. The SI DNA oligonucleotide, a DNA version of SI RNA oligonucleotide, was 
unable to show any competitive effect with [32P]-labelled GLI 230-420 in binding to CRD-BP. 
This clearly demonstrates the specificity of CRD-BP in binding to RNA molecules only. Seven
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additional RNA oligonucleotides (S2-S8) were designed, each having different loop sizes and 
slightly different sequences of nucleotides. S2, S3, S5 and S8  competed with [32P]-labelled GLI 
230-420 RNA for binding to CRD-BP, while S4, S6  and S7 did not compete at all. Surprisingly, 
S7 was not an effective competitor although it has the two loops with the same structure and 
sequence as SI. The reason might be the formation of another more stable secondary structure 
according to MFOLD web server having AG= -4.80 Kcal/mol while S7 structure has AG= -4.00 
Kcal/mol. Structure S8  has the same two stem loop secondary structure as SI but different 
sequences at the loop. It reduced binding to 84% which is not significant as compared to SI. 
These results suggest that both stem loop secondary structure as well as their sequences are 
important in binding to CRD-BP.
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Assessing CRD-BP and its KH variants for ability to bind GLIl and CD44 RNAs
CRD-BP has two RRM and four KH domains (Fig 24). Previous studies have demonstrated the 
importance of the KH domains of CRD-BP orthologs in binding its target RNAs (Git and 
Standart, 2002; Nielsen et al, 2002). Most of these studies were based on deletion analysis where 
truncated proteins were used. However, there are some conflicting results regarding the 
significance of each of the KH domains in respect to their physical interaction with RNA 
substrates. In an effort to understand the contribution of each of the KH domains of CRD-BP in 
binding RNA, site-directed mutagenesis on the G-X-X-G motif at each of the KH domains was 
performed (Barnes et al, submitted). Namely, the first glycine in the G-X-X-G motif was 
mutated to an aspartate.
Table 8  shows the abbreviated names of each of the point mutation KH variants. For instance, 
the KH1 variant has point mutation in GXXG motif (G212D) within KH1 domain whereas the 
KH2 variant has point mutation in GXXG motif (G293D) within KH2 domain. KH1-2 variant 
has point mutations in GXXG motifs with KH1 (G212D) and KH2 (G293D) domains, KH3-4 
variant has point mutations in GXXG motifs with KH3 (G422D) and KH4 (G504D) domains, 
and so on. Two CRD-BP variants with
Table 8. Position of mutation in CRD-BP structural domain
Mutation CRD-BP Structural Domain
Y5A RRM1
D526E KH4 variable loop
G212D G-X-X-G ofKHl
G293D G-X-X-G of KH2
G422D G-X-X-G of KH3
G504D G-X-X-G ofKH4
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point mutation which are not expected to affect RNA-binding ability for use as negative controls 
were also generated CRD-BP variant with point mutation at the RRM1 (Y5A) was selected. 
D526E variant with point mutation within the variable loop located between P2  and P3 in KH4 
domain (Chao et al, 2010) was also generated. Fig24 shows the schematic diagram of the 
structure of CRD-BP and the location of each of the point mutation mentioned above.
C K X H O
Fig 24. Schematic diagrams of CRD-BP: Location of each of the point mutation is shown by 
an arrow (Barnes et al, submitted).
This chapter describes the experiments conducted to compare the RNA binding ability of the 
WT-CRD-BP and its variants on in vitro transcribed [32P] labelled CD44 (nts 2862-3055) and 
GLIl (nts 230-420) RNA substrates.
3.1 Methodology
3.1.1 Purification and dialysis of WT-CRD-BP and its variants
All of the recombinant proteins used in this study were purified by Mr. Mark Barnes and Mr. 
Gerrit Van Rensburg using the method described in Chapter 2. WT-CRD-BP and its variants 
were dialysed as described in Chapter 2. The BCA protein assay kit (Catalog # PI23225, 
Thermo Scientific) was used to quantify all proteins.
3.1.2 Generation of [32P] -labelled CD44 and GLIl RNAs
. GLI nts 230-420 DNA template was synthesized as described in Chapter 2. The CD44 nts 
2862-3055 DNA template was made by Mr. Mark Barnes. In-vitro transcription using T7 
polymerase was done to generate CD44 nts 2862-3055 and GLIl nts 230-420 RNA substrates of
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required size and gel purified as described in Chapter 2. Radioactivity of RNA was checked 
using scintillation counter.
3.1.3 Radiolabelled EMSA using [32P] labeled CD44 and GLIl RNAs 
After in-vitro transcription of CD44 nts 2862-3055 and GLIl nts 230-420 RNA substrates, 
EMSA reaction was performed using various concentrations of the WT CRD-BP and its variants. 
For each reaction tube, ~50,000 cpm of [ P] labelled RNA substrate was added. EMSA binding 
reaction was performed and resolved on 4% non-denaturing polyacrylamide gel as described in 
Chapter 2.
3.2 Results
After synthesis of [32P] labelled CD44 and GLIl RNAs of expected size and purity, EMSA 
reactions using dialysed recombinant proteins were performed.
Fig. 25 shows the EMSA results in comparing the binding profile of the WT CRD-BP and its 
variants on CD44 RNA nts 2862-3055.
As shown in Fig. 25A, theY5A and D526E variants exhibited binding profiles which are 
comparable to the WT-CRD-BP. These results were expected because location of these 
mutations lies outside the KH domains known to be critical for RNA binding (Chao et al, 2010). 
KH1, KH2 and KH3 variants showed reduction in binding as compared to the WT-CRDP. 
Interestingly, KH4 binding ability was significantly reduced as compared to the WT-CRD-BP 
(Fig 25C). Surprisingly, all KH variants with mutation at two G-X-X-G motifs (KH1-2, KH1-3, 
KH1-4, KH2-3 and KH2-4), with the exception of KH 3-4 variant, showed complete loss of 
binding ability (Fig 25).
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Fig 25. EMSA in assessing the binding profile of the WT-CRD-BP and its variants on CD44 
RNA: [32P]-labeled CD44 RNA nts 2862-3055 was incubated with various concentrations of 
either the WT-CRD-BP or its variants in EMSA reaction as described in the Methodology. The 
reaction mixture was resolved on 4% native polyacrylamide gels. Data shown are representatives 
of replicate experiments (n = 4).
Fig. 26 shows the EMSA results in comparing the ability of the WT CRD-BP and its variants 
for binding to GL/1 RNA nts 230-420.
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Fig 26. EMSA in assessing the WT-CRD-BP and its variants for binding to GLIl RNA:
[32P]-labeled GLIl RNA nts 230-420 was incubated with various concentrations of either the 
WT-CRD-BP or its variants in EMSA reaction as described in the Methodology. The reaction 
mixture was resolved on 4% native polyacrylamide gels. Data shown are representatives of 
replicate experiments (n = 4).
The binding ability of Y5A and D527E variants for GLIl RNA was slightly reduced as 
compared to the WT-CRD-BP (Fig 26A). As shown in Fig. 26B, KHl variant showed significant 
reduction in binding GLI RNA as compared to the WT-CRD-BP. Surprisingly, KH2 variant was 
completely incapable of binding to GLIl RNA (Fig. 26B). KH3 and KH4 variants showed 
binding profiles which are comparable to the WT-CRD-BP. Interestingly; all KH variants with
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Fig 27 Saturation binding of CRD-BP and its variants on CD44 RNA: The EMSA results 
shown in Fig 25 plus another two EMSA results using two separate protein preparations were 
pooled and quantified using densitometry. The saturation binding data for each protein which 
exhibited typical binding characteristics are shown. The Hill equation was then used to calculate 
the dissociation constant (IQ). (n=4)
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Fig 28. Saturation binding of CRD-BP and its variants on G LIl RNA: The saturation 
binding data shown were generated from the EMSA results in Fig 26 and two EMSAs using two 
separate protein preparation. The Hill equation was then used to calculate the dissociation 
constant (Kj).
point mutation in G-X-X-G motif at two KH domains completely lost their ability to bind GLIl 
RNA (Fig 26).
The saturation binding data pooled from four biological replicate EMSAs are shown in Figs.27 
and 28. The Hill equation was then used to calculate the dissociation constant (Ka) for each of 
the protein that binds CD44 and GLIl RNAs.
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Summary of the Ka values of all KH variants with CD44 and GLIl RNAs is shown in Table 9. 
Statistical analysis was performed using student-t test method.
Table 9. Summary of the IQ values of CRD-BP and its variants for binding to CD44 and 
GLIl RNAs
Protein CD44 nts 2862-3055 GLIl nts 230-420
WT-CRD-BP 149.32±8.42 288.07±23.49
Y5A 100.1 l±16.41**a 384.36±90.42g
D526E 90.65±1.64**b 313.93±67.13h
KH1 211.18±34.94c No Binding*
KH2 250.27±26.72**d No Binding
KH3 219.32±19.35**e 466.18il36.081
KH4 No Binding* 201.77±10.759**j
KH1-2 No Binding No Binding
KH1-3 No Binding No Binding
KH1-4 No Binding No Binding
KH2-3 No Binding No Binding
KH2-4 No Binding No Binding
KH3-4 133.33±11.04f No Binding
* Binding was not sufficient to calculate Ka.
** P<0.05, P-values of all the KH variants for CD44 and GLIl were a=0.0371, b=0.0005, 
c=0.1016, d=0.0091, e=0.0143, £=0.2933, g=0.2858, h=0.6970,1=0.1890, j=0.0317
3.3 Discussion
The goal of this Chapter was to assess the role of each of the KH domains of CRD-BP in 
binding to CD44 (nts 2862-3055) and GLIl (nts 230-420) RNAs. At the outset of this project, 
one of the main concerns was the possibility of major alteration to the overall protein structure 
upon mutation at the first glycine of G-X-X-G motif in the KH domain. Fortunately, it has been 
confirmed that the WT CRD-BP and all CRD-BP variants exhibited similar, if not identical,
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circular dichroism spectra suggesting that there is no global secondary structure changes upon 
point mutation (Barnes et al, submitted).
In case of binding to CD44 RNA nts 2862-3055, single point mutation did appear to 
moderately affect the binding ability CRD-BP. But the greatest effect was seen with KH4 
variant where binding efficiency was significantly retarded resulting in unmeasurable Ka value. 
With the exception of KH3-4 variant, all CRD-BP variants with point mutation in G-X-X-G 
motifs at two KH domains, completely lost ability to bind CD44 RNA. This result suggests that 
the G-X-X-G motif in KH3 and KH4 in combination does not appear to play critical role in 
binding CD44 RNA, rather there might be some other binding sites available within the KH3-4 
di-domains responsible for binding efficiently to CD44 RNA.
In the case of binding to GLIl RNA nts 230-420, KH2 variant showed complete lost of ability 
to bind, suggesting that the first glycine of G-X-X-G motif in KH2 domain play an important 
role in binding GLIl RNA. KH1 also showed much reduced binding, suggesting that the first 
glycine residue in the G-X-X-G motif in KH1 domain also plays an important role in binding to 
GLIl RNA. Surprisingly, all variants with point mutation in G-X-X-G motif at two KH domains, 
including the KH3-4 variant, completely lost their ability to bind GLIl RNA.
The overall results suggest that CRD-BP binds to CD44 and GLIl RNAs differently. It is likely 
that the sequence and hence the structure of RNA plays an important role in binding CRD-BP. 
All four KH domains seem important in binding to CD44 and GLIl RNAs. It seems that CD44 
and GLIl RNAs might bind with different KH domains of CRD-BP. The observation that 
mutation at two KH domains more significantly deteriorated the binding ability of CRD-BP 
supports the hypothesis that RNA loops around two KH domains when it binds with CRD-BP 
(Chao et al, 2010).
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The K<j values of WT CRD-BP for binding to CD44 and GLIl RNAs were slightly different. 
The Kd value for CD44 RNA was lower than that for GLIl RNA suggesting that CRD-BP binds 
more avidly to CD44 RNA.
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Chapter 4
Investigating the regulation of GLIl mRNA expression by CRD-BP in cancer cells
In light of the successful characterization of CRD-BP-GLIl RNA interaction in vitro as 
described in Chapter 2, studies described in this Chapter were undertaken to explore the CRD- 
BP-GLI1 mRNA interaction in cells. Specifically, this chapter describes the studies examining 
the effect on GLIl mRNA level in two different cancer cells lines upon overexpression or 
knockdown of CRD-BP. The two cell lines used were HCT116 human colon cancer cells and 
T47D human breast cancer cells. The mRNA levels of GLIl and CRD-BP were measured using 
RT-qPCR technique. 2’O-methyl modified RNA oligonucleotides (IDT) were used to examine 
their effects on GLIl mRNA levels in cells.
4.1 Methodology
4.1.1 Detection of GLIl mRNA levels in cell lines
Using RT-qPCR, the basal levels of GLIl mRNA were measured in seven different cell lines 
which include HCT116, MCF-7, SKOV3, HT-29, SKVCR 2.0, MDA-MB-231 and T47D.
4.1.1.1 Plating of cells in 6-well plates
Cells were plated in 6-well plates at the density of 2.5* 104 cells/mL. Three wells were 
designated for each cell line. Cells were cultured in Minimum Essential Media (Life 
Technologies) containing 10% Fetal Bovine Serum. Plates were incubated at 37°C in 5% CO2 
for ~3 days.
4.1.1.2 Total RNA extraction
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Total RNA was extracted from cells using the nnWana™ miRNA Isolation Kit (Life 
Technologies). The cells were first washed with 2 mL of PBS per well. 200 pL of lysis buffer 
was added into each well and cells lysate was pipetted up and down to mix well. Further mixing 
was done by using SP Vortex. 60 pL of homogenate additive was added to the above lysate 
followed by incubation on ice for 10 minutes. Acid-phenol: chloroform (600 pL) was added to 
the lysate, vortexed and spun at 10,000 x g for 5 min. The aqueous layer was collected and 100% 
ethanol was added to it. The solution was then loaded onto the mirVana Filter Cartridge to 
immobilize the RNA. RNA was washed with wash solutions and at the end 95°C heated nuclease 
free water was added to the center of the column. RNA was eluted by spinning it at 10,000 x g 
spin for 1 minute. RNA was quantified using Nano Drop.
4.1.1.3 DNase treatment
Total RNA extracted from seven cell lines were DNase treated using Ambion® DNA free™ kit. 
One pg total RNA was added with 1 pL DNAsel buffer, 1 pL DNasel and sufficient amount of 
nuclease free water to make up the total volume 10 pL. Reaction was incubated at 37°C for 20- 
30 minutes. One pL DNase inactivation reagent was added and mixed. Reaction mixture was 
incubated at room temperature for 2 minutes with occasional mixing. Centrifugation at 10,000 * 
g was performed for 1.5 minutes and RNA was collected.
4.1.1.4 cDNA synthesis
cDNA was synthesized using BIO-RAD iScript™ cDNA Synthesis Kit. DNase-treated RNA 
was mixed with 4 pL 5 * iScript mix, 1 pL reverse transcriptase enzyme and nuclease free water. 
Total reaction volume was 20 pL. Synthesis of cDNA was performed using thermo cycler. The 
program used to make first strand cDNA was 25°C-5 minutes, 42°C -30 minutes, 85°C-5 
minutes, 4°C forever.
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4.1.1.5 RT-qPCR
Following cDNA synthesis, RT-qPCR reactions were mixed by adding 6 pL cDNA, 12.5 pL 
iQ™ SYBR® Green Supermix (Bio-Rad), 1.0 pL GLIl forward primer (10 pM), 1.0 pL GLIl 
reverse primer (10 pM) and 4.5 pL nuclease-free water. GLIl gene primer sequences are shown 
in Table?? The reaction mixtures (25 pL) were added to 96-well PCR plate (Axygen Scientific 
Inc) and placed in a Bio-Rad iQ5 cycler where the cDNA was amplified using a two-step PCR 
reaction. GUI mRNA level was analysed using iQ5, version 2.0 software. Prior to all RT-qPCR 
experiments, optimal temperature for GLIl primers was determined using melt-curve analysis.
4.1.2 Knockdown CRD-BP in HCT116 and T47D
CRD-BP knocked down experiments were done using siRNA against CRD-BP in both 
HCT116 and T47D cells. After CRD-BP knocked down GLIl mRNA level was measured by 
performing qRT-PCR.
4.1.2.1 Transfecting cells with dsiRNA and performing RT-qPCR of GLIl
Cells were plated in 6-well plates as described above. After -20 hours, cells were transfected 
with dsiRNA against CRD-BP. Three wells were transfected with 20 nM dsiRNA, while three 
wells were transfected with 20 nM NCI using Lipofectamine 2000 reagent (Invitrogen). NCI 
was used as a negative control. Following transfection, cells were incubated at 37°C in 5% CO2  
for 48 hours. Total RNA extraction was done followed by RT-qPCR to measure GLIl mRNA 
level.
4.1.2.2 RT-qPCR of CRD-BP
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RT-qPCR of CRD-BP was done to confirm down regulation of CRD-BP mRNA levels after 
transfecting with dsiRNA against CRD-BP. TaqMan® probes were used for detecting CRD-BP 
and P-actin mRNAs. The primers and probes used are shown in Table 9. These primers and 
probes were previously optimized in Dr. Lee’s laboratory. CRD-BP RT-qPCR reaction was
(ftprepared with 12.5 pL iQ supermix (BioRad ), 1 pL forward primer (10 pM), 1 pL reverse 
primer (10 pM), 1 pL Fam-TMRA probe (IDT), 8.5 pL milliQ water and 1 pL cDNA to make 
up volume 25 pL. For P-actin RT-qPCR, the same method was employed except that 1 pL of 
1/10 time diluted cDNA was used. The reaction mixtures were added to 96-well PCR plate 
(Axygen Scientific Inc) and placed in Bio-Rad iQ5 cycler where the cDNA was amplified using 
a two-step PCR reaction, fl-actin. was used as a reference gene and expression levels of CRD-BP 
were normalized by N C I.
Table 10. Primer and probe sequences of CRD-BP and p-actin  used in qRT-PCR Taqman 
approach
Target Gene Primer Sequences_____________________________________________
CRD-BP Forward: 5’-AACCCTGAGAGGACCATCACT-3’
Reverse: 5 ’ -AGCTGGGAAAAGACCTACAGC-3 ’
Probe: 5’-/56-FAM/TGTTGCAGGGCCGAGCAGGA/36-TAMSp/-3’
P-actin Forward: 5 ’-TTGCCGACAGGATGCAGAAGGA-3 ’
Reverse: 5 ’ -AGGTGGACAGCGAGGCCAGGAT-3 ’
Probe: 5’-/56 FAM/ATGAAGATCAAGATCATTGCTCCTCCTG/36- 
______________ TAMSp/-3’___________________________________________________
4.1.2.3 RT-qPCR of G LIl and P -actin
RNA was DNase treated and cDNA was synthesized as described above. Following cDNA 
synthesis, RT-qPCR reaction was performed as described above to measure GLIl mRNA level. 
P-actin was used as a house keeping gene. In order to determine P-actin mRNA level, 1 pL 1/10 
time diluted cDNA was mixed with 12.5 pL iQ™ SYBR® Green Supermix (Bio-Rad), 1.0 pL (3-
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actin forward primer (10 pM), 1.0 pL P-actin reverse primer (10 pM) and 9.5 pL nuclease-free 
water. P-actin primers had been previously optimized (Barnes et al, 2007). For GLIl RT-qPCR, 
the same method was employed except that 6 pL cDNA were used. Difference in GLIl mRNA 
level after overexpressing WT-CRD-BP was analysed using iQ5, version 2.0 software, p-actin 
was used as a reference gene and expression level of GLIl mRNA was normalized with the help 
of pcDNA-FLAG-vector.
Table 11. Primer sequences of GLIl and p-actin  used in SYBR Green qRT-PCR method
Target Gene Primer Sequence
GLIl Forward: 5 ’-CCCAATCACAAGTCAGGTTCCT-3 ’ 
Reverse : 5 ’-CCTATGTGAAGCCCTATTTGCC-3 ’
p  -actin Forward: 5 ’-TTGCCGACAGGATGCAGAAGGA-3 ’ 
Reverse: 5 ’ -AGGTGGACAGCGAGGCCAGGAT-3 ’
4.1.3 Overexpressing CRD-BP in HCT116 and T47D cells
To investigate the possible regulation of GLIl mRNA expression by CRD-BP, CRD-BP was 
overexpressed in both HCT116 and T47D cells. Cells were plated in 6-wells plate at the density 
of 7.5x 104 cells/mL as mentioned above.
4.1.3.1 Transfecting cells with pcDNA-FLAG-CRD-BP and pcDNA-FLAG- vector
Twenty hours after plating, cells were transfected with pcDNA-FLAG-CRD-BP or pcDNA- 
FLAG vector plasmids. PcDNA-FLAG vector was used as a negative control in this experiment. 
Each well was transfected with 2 pg plasmids using Lipofectamine 2000 reagent (Invitrogen). 
Following transfection, cells were incubated at 37°C in 5% CO2 for 48 hours. Following 
incubation, total RNA was extracted as described above and the quantity of RNA was
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determined using Nano drop Spectrometer. RT-qPCR of CRD-BP, GLIl and fi-actin was 
performed as mentioned above. Results of RT-qPCR were generated by iQ™ 5 optical system 
software (Bio-Rad) after normalizing to vector.
4.1.4 Effect of modified RNA oligonucleotides on GLIl mRNA level in cells
Upon establishing the cell line model where CRD-BP-GL/7 mRNA interaction can be 
observed, the next step was to study the effect of RNA oligonucleotide capable of breaking 
CRD-BP-GL/7 RNA interaction in-vitro as described in Chapter 2. Two 2’ O-methyl modified 
RNA oligonucleotides were ordered from IDT. One RNA oligonucleotide (SI) was capable of 
breaking interaction in-vitro while the other (S4) was unable to show any effect on CRD-BP- 
GLI1 RNA interaction in-vitro as described in Chapter 2.
4.1.4.1 Transfecting Cells with modified RNA oligonucleotides
Cells were plated in 6-well plates as described above. After ~20 hours, cells were transfected 
with 250 nM or 100 nM 2’ O-methyl modified SI or S4. Cells were also transfected with the 
negative control Scrambled-Negative oligonucleotide. Primer sequences of SI and S4 are shown 
in Chapter 2. Cells were incubated at 37°C in 5% CO2 for 48 hours before subjected to total 
RNA extraction as described above. qRT-PCR of GLIl, CRD-BP and f-actin was performed as 
described above.
4.2 Results
4.2.1 Primer optimization
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Melt-curve analysis was performed to analyze the specificity of the GLIl primers given in 
Table 10. The annealing temperature of 60°C was used. As shown in Fig. 29, the single band 
produced at ~81°C confirms the specificity of the primer.
Met Pet* Chart: Data 2012-09-181221 .opd
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Fig 29. Melt curve analysis of GLIl primers: Melt curve analyses of GLIl primers were done 
at 60°C using total RNA extracted from T47D cells. Single peak of product confirms the 
specificity of GLIl primers.
4.2.2. Detection of G LIl mRNA level in cell lines
The basal GLIl mRNA levels were measured in seven different cancer cell lines. Their mean 
Ct values are listed in Table 11. The lower Ct value indicates higher GLIl mRNA level. Based on 
the data in Table 11,1 conclude that all the seven cell lines expressed detectable level of GLIl
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mRNA and can be used for further studies. SKOV3 and SKVCR2.0 appeared to express the 
highest level of GLIl mRNA, while MDA-MB-231 and MCF7 cells expressed the lowest level.
Table 12. Ct values of seven cancer cell lines
CeU Line Mean Ct Values
HCT116 26.65
MCF-7 29.53
SKOV3 24.04
HT-29 28.01
SKVCR2.0 25.28
MDA-MB-231 30.66
T47D 29.50
4.2.3 Knockdown CRD-BP using dsiRNA
To determine if the CRD-BP-GL/7 mRNA interaction exists in T47D and HCT116 cells, 
endogenous CRD-BP was knocked down with a specific dsiRNA.
A B
NCI siRNA siRNA
Fig 30. Effect of knocking down CRD-BP on G LIl mRNA level in HCT116 cells:
Knockdown CRD-BP was achieved by using dsiRNA. Data was pooled from two different 
biological replicates. Levels of (A) CRD-BP mRNA as well as (B) GLIl mRNA were decreased. 
The Error bars represent mean standard deviation (n = 2) obtained from two biological replicates.
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. As shown in Fig. 30A, CRD-BP mRNA expression level was reduced by -10 fold in HCT116 
cells upon transfection with the specific dsiRNA against CRD-BP. As shown in Fig. 30B, upon 
knock down of CRD- BP, GLIl mRNA level was reduced about 4-fold in HCT116 cells. Mr. 
Daud Akhtar, a member in Dr. Lee’s lab, had assisted me in the knocked down experiments 
described in Figs 30 and 31.
A
siRNA
B
SiRNA
Fig 31. Effect of knocking down CRD-BP on G LIl mRNA level in T47D cells: Knockdown 
CRD-BP was done using a specific siRNA. (A) CRD-BP as well as (B) GLIl mRNA level was 
measured upon CRD-BP knocked down. The data were pooled from three biological replicates 
and the error bars represent mean standard deviation (n = 3).
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As shown in Fig 31, upon successful knocked down of CRD-BP to ~5 fold in T47D cells, GUI 
mRNA was decreased by ~ 4 to 5-fold.
4.2.4 Overexpressing CRD-BP in HCT116 and T47D cell lines
To further investigate if CRD-BP can regulate GUI mRNA expression, I transfected cells with 
plasmids carrying CRD-BP cDNA driven by the CMV promoter. This was to investigate the 
effect of overexpressing CRD-BP on GUI mRNA level. Theoretically, if association of CRD- 
EP-GU1 mRNA exists in cells, GUI mRNA level should increase. Unfortunately after 
performing three biological replicates of HCT116 cells, there was no appreciable change in GUI 
mRNA level. The data from three biological replicates were pooled to make the graph shown in 
Fig 32. CRD-BP mRNA levels could be checked to confirm overexpression of CRD-BP, but due 
to unavailability of CRD-BP primers and Taqman probe at that time of the experiment this was 
not performed.
pcDNA-FLAG-CRD-BPpcDNA-FLAG vec to r
Fig 32. The effect of over-expressing CRD-BP on GLI1 mRNA level in HCT116 cells:
Overexpression of CRD-BP was done by using FLAG-CRD-BP plasmid in HCT 116 cells. 
Three biological replicates were pooled. The error bars represent mean standard deviation (n = 
3).
However, upon overexpressing CRD-BP in T47D, the level of GUI mRNA was found to 
increase by about ~7 fold. This is consistent with the model that CRD-BP binds and stabilizes
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GUI mRNA transcript. The data from two biological replicates were pooled to draw the graph 
shown in Fig 32.
To confirm the success of transfection and the over-expression of CRD-BP mRNA in 
transfected cells, RT-qPCR was performed to measure CRD-BP mRNA levels. Unlike in 
HCT116 cells, increased expression of CRD-BP mRNA to ~300-fold was observed, confirming 
the success of the overexpression experiment (Fig 33). Indeed, there was a concomitant 
increased in G U I mRNA levels (~ 6.5-fold increase) in the same samples.
A B
pcOHA-FLAG vector pcDNA-FUM RM P
Fig 33. Overexpressing CRD-BP in T47D cells and checking CRD-BP and GLI1 mRNA 
levels by doing RT-qPCR: Overexpression of CRD-BP was done by using FLAG-WT-CRD- 
BP plasmid in T47D cells. (A) WT-CRD-BP as well as (B) GUI mRNA level was increased. 
Data from two biological replicates was pooled together. Error bars represent mean standard 
deviation
The data from two biological replicates was pooled to draw the graph shown in Fig 33. Taken 
together, our data so far supported the existence of the CRD-BP-GL/7 mRNA interaction in 
T47D human breast cancer cells.
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4.2.5 Effect of 2’ O-methyl SI and S4 RNA Oligonucleotides on GLI1 mRNA levels in 
cells
Having shown that the interaction between CRD-BP and GLI1 mRNA is present in T47D cells, 
I then proceeded to test the RNA oligonucleotides. As shown in Fig 34, after transfecting T47D 
cells with 250 nM or 100 nM 2’ O-methyl SI oligonucleotides, GLI1 mRNA level was reduced 
by ~5-fold. SN was used as the negative control and expression of G UI mRNA was normalized 
to that of SN. S4, an RNA oligonucleotide which could not break CRD-EP-GLI1 RNA 
interaction in vitro (Chapter 2), was used as an additional negative control. As shown in Fig 
34A, S4 exerted a higher expression level of GUI
A B
Fig 34. Effect of SI and S4 2’ O-methyl RNA Oligonucleotides on GLI1 mRNA level in 
T47D cells: T47D cells were transfected with Scrambled-Negative (SN), 2’ O-methyl SI or S4 
RNA oligonucleotides at two different concentrations, (A) 250 nM And (B) 100 nM. GUI 
mRNA levels were measured by qRT-PCR. Data shown were pooled from three biological 
replicates and the error bars are standard deviation
mRNA than SN at 250 nM. Surprisingly, at 100 nM concentration, S4 reduced GUI mRNA 
expression level by about ~2 to 3-fold (Fig 34B). Mr. Daud Akhtar also assisted me in 
performing the experiments described in Fig 34. The data pooled from three biological replicates 
were used to draw the graph shown in Fig 34.
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As shown in Fig.35, after transfecting HCT116 cells with 250 nM SI oligonucleotide, there 
was 40% decrease in GUI mRNA level. However, at 100 nM, SI oligonucleotide had no effect 
on GUI mRNA level. At both 100 and 250 nM, had no significant effect on GLI1 mRNA level 
inHCT116 cells
A
B
'C 1 .2
"D 0 .8
X I 0.6
m 0.4
SN S4 SI
Fig 35. Effect of SI and S4 V  O-methyl RNA Oligonucletides on GLI1 mRNA level in 
HCT116 cells: HCT116 cells were transfected with Scrambled-Negative (SN), 2’ O-methyl SI 
or S4 RNA oligonucleotides at two different concentrations, (A) 250 nM and (B) 100 nM. GUI 
mRNA levels were measured by qRT-PCR. Data shown is a representative of two biological 
replicates.
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4.3 Discussion
CRD-BP has been shown to bind GUI mRNA and increases its stability and transcriptional 
activity (Noubissi et al, 2009). To confirm such relationship between CRD-BP and GLI1 mRNA 
in our own hands, I performed experiments to knockdown as well as to overexpress CRD-BP in 
HCT116 and T47D cells. Upon establishing the existence of CRD-BP-GZJ/mRNA interaction in 
cells, the next step was to investigate the effect of specific RNA oligonucleotide that was capable 
of breaking CRD-BP-GL/7 RNA interaction in-vitro (see Chapter 2).
The first step was to choose a cell-line model to investigate CRD-BP-GZJ7 mRNA interaction 
in cells. Out of the 7 cell lines examined, HCT116 and T47D cell lines were chosen for 
subsequent experiments due to their higher basal GUI mRNA levels and their higher 
proliferative rate. Overexpression of CRD-BP was performed by transfecting both cell lines with 
the plasmid pcDNA-FLAG-CRD-BP. T47D cells showed an increase in both CRD-BP and GUI 
mRNAs level suggesting that GUI mRNA levels are under the influence of CRD-BP in this cell 
line. On the contrary, there was no change in GUI mRNA level in HCT116 upon over­
expression of CRD-BP. It is possible that in HCT116 cells, GUI mRNA was already at 
relatively high level and hence no further up-regulation can be observed. Alternatively, there is 
no direct link between CRD-BP and GUI mRNA in HCT 116 cells.
After performing the overexpression experiments, CRD-BP knockdown experiments were 
conducted to study its effect on G UI mRNA level. The results clearly demonstrated that upon 
knocked down of CRD-BP mRNA, there was decrease in GUI mRNA levels in both T47D and 
HCT116 cell lines, suggesting that the physical interaction between CRD-BP and GUI mRNA 
exists in these cells. Hence, both cell lines were chosen for further studies on the effect of 2’ O- 
methyl modified RNA oligonucleotides.
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HCT116 and T47D cells were transfected with two different concentrations of 2’ O-methyl 
RNA oligonucleotides SI and S4. S4 was used as a negative control in this study. At 250 nM 
concentration of SI oligonucleotide, both cell lines showed reduction in GUI mRNA levels. At 
100 nM Oligonucleotides, T47D cells showed reduction in GUI mRNA levels while HCT 116 
did not show any change in GUI mRNA level. This suggested that T47D cells may be more 
sensitive to RNA oligonucleotide than the HCT 116 cells. The results showed that treatment of 
both cell types by SI RNA oligonucleotide caused decrease in GUI mRNA level. The proposed 
mechanism of action of SI is that it competes with the endogenous GUI mRNA for binding to 
CRD-BP, resulting in less availability of CRD-BP to bind and protect the endogenous GUI 
mRNA. Hence, this subsequently led to the destabilization of GUI mRNA and reduced steady- 
state of the transcript. The immuno-precipitation coupled with qRT-PCR method could be 
performed to confirm that SI is truly capable of breaking CRD-BP-GL/7 mRNA interaction in 
cells. In addition, the SI RNA oligonucleotide can be tested on other cell lines to determine 
whether its effect can be applied broadly in cells where the CRD-BP-GUI mRNA interaction 
exists. For instance, it can be assessed in the following cell lines where GUI mRNA is 
detectable- MCF-7, SKOV3, HT-29, and drug resistant SKVCR 2.0.
CRD-BP has many different mRNA targets such as c-myc, CD44, Kras, MITF and MDR1, and 
MAPK. Transfecting cells with the SI RNA oligonucleotides may change the level of other 
mRNA targets of CRD-BP. This could be an exciting approach to confirm specificity of this 
oligonucleotide.
One of the most important future studies is to determine whether there are phenotypic changes 
upon treatment of cells with the SI RNA oligonucleotide. For instance, MTT growth assay or
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drug sensitivity experiments can be performed to observe potential RNA oligonucleotide effect 
on growth and cell survival.
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Chapter 5
5.1 General discussion
The aims of this research were based on both the basic research point of view, and also the 
applied research point of view. From the basic research point of view, the first goal was to 
investigate the complex formation between CRD-BP and its target mRNAs. The second goal was 
to determine the smallest possible fragments of these mRNAs that are capable of binding to 
CRD-BP. Using UV cross-linking experiment, ~ 950 nts GUI mRNA fragment corresponding to 
nts 41-990 was found to physically associate with CRD-BP (Noubissi et al, 2009). Using 
electrophoretic mobility shift assay, the MDRl RNA spanning nts 746-962 was previously 
shown to have high affinity for CRD-BP (Sparanese and Lee, 2007). One of the purposes of this 
study was to determine the minimum size of GUI as well as MDRl RNA fragments that still 
bind to CRD-BP. This was done for two reasons: (1) so that future studies can be aimed at 
comparing and contrasting the structure and sequences of all the small RNA binders of CRD-BP 
to see if there are any commonalities; (2) by knowing the smallest RNA binder, we can design 
fluorescent RNA for use in fluorescent anisotropy experiment to conveniently study CRD-BP- 
RNA interaction and to rapidly screen for inhibitors of CRD-BP-RNA interaction.
Another important basic question to address was the importance of each of the KH domains of 
CRD-BP in binding to its target transcripts. In Dr. Lee’s lab, point mutation in all four KH 
domains of CRD-BP had been successfully generated using site-directed mutagenesis (Barnes et 
al, submitted). One of the goals of this thesis was focussed on assessing the binding affinity of 
CRD-BP KH variants for CD44 and GUI mRNAs.
From the applied research point of view, this study mainly focussed on finding molecules that 
can inhibit CKD-EP-GU1 RNA interaction. Breaking CRD-BP-GL/7 RNA interaction can be 
used to specifically target CRD-BP and GUI, and would represent a novel method to down
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regulate their oncogenic function. This approach of inhibiting CRD-BP has some advantages. 
Firstly, due its ability to interact with various mRNA targets which encode for oncoproteins, the 
possibility of inhibiting several different signaling pathways involved in cancer development 
appears to be a very attractive therapeutic approach. Secondly, since my goal is to inhibit 
specific CRD-BP-RNA interaction the chances of inhibiting other functions performed by this 
protein are minimized.
5.2 Assessing CRD-BP-RNA interaction using fluorescent EMSA
In an effort to conveniently study CRD-BP-RNA interaction and to rapidly find inhibitors of 
CRD-BP-RNA interaction, I aimed to first develop the fluorescent EMSA in the lab. Fluorescent 
EMSA was performed using in-vitro transcribed fluorescent MDRl RNA nts 739-922 and 
various concentration of CRD-BP. Fluorescent EMSA is a well-established in-vitro method used 
to detect protein-nucleic acid interaction (Steiner and Pfannschmidt 2009; Chao et al, 2010). 
This non-radioactive method was employed due to its safety and cost effectiveness. 
Unfortunately, the fluorescent signal of the specific MDRl RNA-CRD-BP complex was too 
weak to warrant quantification purposes (Fig 13 in Chapter 2). Such effect could be the result of 
non-specific aggregation of CRD-BP-RNA complex in the wells of the gel.
The fluorescein labelled UTP is a large molecule having molecular weight of 994.7 g/mol, 
which is almost double the molecular weight of non-labelled UTP. Hence, the internal labelling 
of transcript with fluorescein-labeled UTP had undoubtedly led to increased RNA size. Several 
polyacrylamide gel concentrations (4 to 8%) were used in an attempt to resolve this issue, but 
unfortunately it did not help to decrease the accumulation of protein-RNA complexes in the 
wells of gels. 3’ labelling of fluorescent RNA was used as an alternate choice but this strategy 
failed to generate good quality fluorescently labelled transcript (data not shown). After multiple 
failed attempts, it was deemed that fluorescent EMSA was not useful in quantifying CRD-BP -
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RNA interaction. Hence, for the rest of the work, radiolabelled EMSA was employed to study 
CRD-BP-RNA interaction in-vitro.
5.3 Assessing GUI and MDRl RNA-CRD-BP interaction using [3ZP]-radiolabeled EMSA
[32P]-radiolabeled EMSA is an established method commonly used in Dr. Lee’s lab to study 
protein-RNA interaction in-vitro (Sparanese and Lee; 2007, Kim et al, 2011 and 2014; Barnes et 
al, 2014). [ P]-radiolabeled EMSA was performed to assess the binding ability of each fragment 
of GUI and MDRl RNAs to CRD-BP. Interestingly, out of five truncated fragments of GUI 
RNA each having -190 nts, only one fragment G LI230-420 showed strong binding with CRD- 
BP as shown in Fig 14A in Chapter 2. Surprisingly, GLI 420-610 showed inability to bind CRD- 
BP. G U  36-231, GLI 610-800 and GLI 800-990 also did not show affinity for CRD-BP as shown 
in Fig 14. It was observed that intensity of free RNA of all three fragments decreased upon 
addition of higher concentrations of CRD-BP as shown in Fig 14B in Chapter 2. This decrease 
was mainly due to the immobility of RNA-protein aggregation in the wells at higher protein 
concentration. Such protein aggregation problem was finally resolved during the course of this 
work by changing the protein dialysis protocol. After successfully narrowing the binding region 
of GUI RNA down to -190 nts, eight truncated fragments of GLI1 RNA nts 230-420 were in- 
vitro transcribed using [32P]-radiolabeled UTP and tested for binding to CRD-BP. These 
transcripts were 3’ and 5’ truncated fragments of GU  230-420 RNA. The rationale of designing 
these fragments was to locate the smallest CRD-BP-binding region on GUI RNA. After 
performing [32P]-radiolabeled EMSA with all these truncated RNA fragments, GLI 320-380 
region was found to be the most important region for binding CRD-BP. MFOLD generated 
secondary structure of GLI 320-380 shows the presence of two stem loops. This predicted 
secondary structure of GLI 320-380 was remarkably similar to MFOLD-generated secondary 
structure of CD44 RNA nts 2862-2930 that binds CRD-BP (King et al, 2014). The secondary
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structures of both these RNAs are shown in Fig 18 in Chapter2. As the KH34 domains of CRD- 
BP have been shown to act as di-domains (Chao et al, 2010), it is tempting to speculate that the 
two stem loops of RNA interact with two different KH domains as a possible mechanism of 
binding.
MDRl 746-962 nts region binds with high affinity to CRD-BP (Sparanese and Lee, 2007). The 
goal was to map the smallest region of MDRl RNA that could bind CRD-BP. All 3’ and 5’ 
truncated RNA fragments which contain the 739-850 nts region showed either weak or strong 
binding with CRD-BP. Surprisingly, MDRl 779-881 binding affinity was similar to the foil 
length MDRl RNA 739-921, suggesting the importance of 779-881 nts region in bindingCRD- 
BP.
An interesting finding from these studies was the observation that there was a general 
reduction in the binding ability of smaller RNA fragments as compared to larger transcripts as 
shown in Fig 15-17. GLI1 as well as MDRl RNA showed similar characteristic in that there was 
reduction in binding affinity as the length of transcripts was reduced. These results are also 
consistent with the CD44 RNA mapping results (King et al, 2014). X-ray crystal studies of KH3 
and KH4 domains of ZBP1 suggest the looping of RNA around two KH domains as an important 
step for RNA binding to ZBP1 (Chao et al, 2010). It is likely that longer RNA strand can 
undergo such 180° shift and bind with both domains; while it may be more difficult for smaller 
RNA fragments to orient themselves in such a way to make a connection with two KH domains. 
Hence, smaller RNA fragment generally have reduced ability to bind CRD-BP.
5.4 Breaking GLI1RNA-CRD-BP interaction in vitro
After successfully mapped GLI1 RNA region that binds CRD-BP, the next step was to find 
molecules capable of breaking this physical association in-vitro. A recent paper described the
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first attempt to screen small molecule inhibitors of IMP 1/CRD-BP (Lily et al, 2013). However, it 
was recognized that although small molecules have the potential to become therapeutic agent 
they do have limitation in that they are usually toxic to cells (Lily et al, 2013). Previously, 
antisense oligonucleotides have been successfully used to break the interaction between CRD-BP 
and its target RNAs - c-myc (Coulis et al, 2000) and CD44 (King et al 2014). Furthermore, RNA 
oligonucleotides have been considered as safe therapeutic agents (Bouchard et al, 2010). One of 
the goals of this thesis was to investigate the ability of RNA/DNA oligonucleotides to 
specifically break CRD-BP-GZJ7 RNA interaction.
The presence of two stem loops in the predicted RNA structure of both GLI I and CD44 RNAs 
that bind CRD-BP prompted me to investigate the role of these two stem loops in binding CRD- 
BP. To test this hypothesis, RNA and DNA oligonucleotide competitors were designed using the 
MFOLD web server. The first approach was to design DNA and RNA oligonucleotides having 
the exact sequence and structure as that of the two stem loops region of GLI1 RNA (346-382 nts 
region). Theoretically, oligonucleotide having the exact same sequence and structure should 
compete with GLI1 230-420. As expected, the RNA oligonucleotide SI competed with GLU 
230-420 RNA in binding to CRD-BP. The DNA oligonucleotide version, however, did not 
compete with GLI 230-420 RNA, demonstrating the specificity of CRD-BP in binding RNA 
only.
The next step was to investigate the role played by the individual stem loop in binding to CRD- 
BP. To test this hypothesis, S2 to S6 RNA oligonucleotides were designed with the help of the 
MFOLD web server. S2 and S3 had one loop present, while S4, S5 and S6 had one complete 
loop and one loop with reduced size. S2, S3 and S5 competed with the [32P]-radiolabeled GLI 
230-420 to bind CRD-BP, but to a lesser extent than SI. This was as expected because of the 
absence or alteration to one of the stem loops and slight variations in the nucleotide sequence as
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compared to SI. Surprisingly, S4 and S6 were ineffective competitors. The loss of important 
nucleotides from the loop region or changes in the linear part of S4 and S6 may be the 
contributing factor. S7 was designed to test the importance of stem region of both stem loops to 
bind CRD-BP. S7 has different nucleotide sequences in the stem region but has the same 
structure as compared to SI. Surprisingly, S7 did not compete at all. The reason might be the 
formation of another more stable secondary structure of the same sequence having AG greater 
than S7. S8 having different nucleotides at step loom region also showed competition with [ P]- 
radiolabeled GLI 230-420 but again to a lesser extent that SI. In summary, we conclude that not 
only the RNA structure, RNA sequences also play an important role in binding to CRD-BP.
5.5 Comparing the KH variants of CRD-BP for binding to CD44 and GLI1 RNAs
The ability of CRD-BP to make physical interaction with its target transcripts is an important 
step for its function. So, there is a need to thoroughly investigate the mechanism involved in the 
binding of CRD-BP with its target mRNAs. To date, it has been reported that CRD-BP and its 
orthologs bind with its target RNAs through its KH domains but not its RRM domains (Git and 
Standart, 2002; Nielsen et al, 2002). However, it was proposed that the RRM domains might be 
helpful in stabilizing the RNA-protein complexes (Nielsen et al, 2004).
This study focuses on the effect of single and double point mutation at the GXXG motif in the 
KH domains of CRD-BP for binding to GLI1 and CD44 RNAs. The two CRD-BP targets, CD44 
RNA nts 2862-3055 and GUI RNA nts 230-420, were chosen for this study. [32P]-radiolabeled 
EMSA was performed with four single and six double mutants of CRD-BP. Y5A and D526E 
point mutation in CRD-BP were used as negative controls in this study because these mutations 
do not lie within the KH domains.
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All KH variants with single point mutation, except KH4, showed binding with [32P]- 
radiolabeled CD44 RNA as shown in Fig 25. KH4 showed reduced binding and its Kd cannot be 
determined. This suggests that the first Glycine of the G-X-X-G motif in KH4 plays an important 
role in binding to CD44 RNA. All KH variants with double point mutations in the GXXG motif 
of KH domains, with the exception of KH3-4, were completely incapable of binding CRD-BP. 
suggesting that parts within the KH3 and KH4 domains other than the GXXG motif can play 
important role in binding to CD44 RNA. There is also the possibility that with both KH3 and 
KH4 mutations in G-X-X-G motif, CD44 can now change its position and bind with other 
regions within KH3 and KH4 or it could bind with KH domains. The negative controls, Y5A and 
D526E variants, exhibited similar or slightly enhanced binding affinity for CD44 RNA as shown 
in Table 8, Chapter 3.
One of the primary concerns of this study was the structural integrity of the CRD-BP KH 
variants. Circular dichroism spectral analysis showed no global secondary structural changes 
after point mutations at the GXXG motifs in all KH variants (Barnes et al, submitted). However, 
possible local structural changes in the KH domain upon point mutation cannot be ruled out 
because of the limitation of the CD spectroscopy (Barnes et al, submitted).
As far as GLI1 RNA is concerned, KH3 single mutants showed binding, while KH1 and KH4 
showed significant reduction in binding. Interestingly, KH2 did not show any binding with GUI 
RNA. Reduction in binding ability of KH1, KH4 and complete abrogation of binding in case of 
KH2, suggest the importance of first Glycine of G-X-X-G motif in KH1, KH2 as well as KH4 
domains in binding to GUI RNA. All KH variants with double mutation showed complete 
abrogation of binding.
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It has been previously shown that KH domains of IMP1 work in tandem to bind RNA 
substrates (Chao et al, 2010). X-ray crystallography reveals the formation of pseudodimer 
between KH3 and KH4 domains which orients the G-X-X-G motifs of each domain in an 
antiparallel configuration to form the RNA binding surface (Chao et al., 2010).
Fig 36. IMP1 KH3-4 pseudodimer configuration of reveals P-actin RNA-binding 
surfaces. Upon dimer formation, the KH domains adopt an antiparallel configuration that 
requires the RNA to undergo a ~180° bend in order to contact both RNA-binding surfaces; 
indicating that both G-X-X-G motifs of KH3 (Red dots) and KH4 (Blue dots) are required for P- 
actin RNA binding (Chao et al., 2010).
It is reasonable to think that CRD-BP binding mechanism would be similar to its orthologs 
when binding RNA substrates. Therefore, a single mutation within only one of the KH domains 
G-X-X-G motifs may or may not result in reduced binding because RNA may be attached with 
single KH domain. KH double mutant inability to bind with both RNAs seems logical if we 
accept the theory of antiparallel configuration of KH domains. The KH3-4 di-domain adopts the 
antiparallel orientation that changes the RNA in linear position after binding. Similarly, it can be 
assumed that the KH1-3 and KH2-4 di-domains adopt a similar configuration (Chao et al, 2010). 
We can conclude that all possible di-domains combination of KH domains can be important in 
binding with CRD-BP.
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Surprisingly, the double mutant KH3-4 binds to CD44 RNA with similar affinity as that o f the 
WT-CRD-BP. KH3 and KH4 domains of ZBP1 were considered to be important in binding P- 
actin mRNA in-vitro (Farina et al, 2003). X-ray crystal structure of IMP1 KH3-4 didomain 
revealed the necessary RNA-binding surfaces for P-actin zipcode mRNA (Chao et a l, 2010). We 
proposed that the first glycine of G-X-X-G motif might not play important role in binding to 
CD44 RNA. Either there are some other binding sites within KH3-4 didomain that are 
responsible for binding with CD44 or there is a possibility of binding to CD44 using the other di­
domains.
From the above discussion, it can be concluded that the first glycine of G-X-X-G motif may 
not be the sole binding site for RNA. There might be multiple binding regions present within 
each KH domains. Binding profiles of both CD44 and GLI I RNAs are different, suggesting the 
possibility of different binding sites for different RNAs within the KH domains. This study 
shows that single point mutation within a KH domain may or may not reduce the binding ability 
of CRD-BP. However, two mutations at two KH domains show more drastic changes in the 
RNA-binding ability of CRD-BP. Further point mutation within the KH domains may provide 
further insights into the RNA-binding characteristics of CRD-BP.
5.6 Breaking of CRD-BP-GX/7 RNA interaction in cells
After I successfully found RNA oligonucleotide capable of breaking the CRD-BP- GLI I RNA 
interaction in vitro, my next goal was to test the oligonucleotide in cells. The most important first 
step was to choose cell lines that express GLI1 mRNA at basal level. Two cell lines, HCT116 
and T47D, were chosen due to their high proliferative rate and the presence of detectable GLI1 
mRNA levels (Noubissi et al, 2009; Bhuvaneswari et al, 2012).
CRD-BP knocked down experiments were conducted on both cell lines. After transfecting 
cells with dsiRNA against CRD-BP, there was a significant reduction in CRD-BP as well as
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GUI mRNA levels. This result suggests that the physical interaction between CRD-BP and 
GUI mRNA exists in the two cell lines. It also supports the hypothesis of the stabilizing effect 
of CRD-BP on GLI1 mRNA in the two cell lines (Noubissi et al, 2009; Noubissi et al, 2014).
Overexpression of CRD-BP using the pcDNA FLAG CRD-BP plasmid was also done on both 
cell lines. While the GUI mRNA levels were increased in T47D cells, it did not change in 
HCT116 cells. The overexpression of GUI mRNA in T47D cells again supported the hypothesis 
of the physical association of CRD-BP with G UI mRNA and the ability of CRD-BP to protect 
GUI mRNA (Noubissi et al 2009 and 2014). The results with HCT 116 cells might be due to 
inability of the cells to overexpress CRD-BP or due to the saturation of CKD-EP-GLI1 mRNA 
complex. CRD-BP mRNA levels were not measured in HCT116 cells due to unavailability of the 
CRD-BP primers and Taqman probe at that time of the experiments.
After establishing the cell line model to study CRD-BP-GZJ7 mRNA interaction, HCT116 and 
T47D cells were transfected with 2’-0-methyl modified RNA oligonucleotides. At 250 nM 
concentration of SI, there was a four-fold decrease in GUI mRNA levels in T47D, while in 
HCT 116 the level was reduced by less than two-fold. Differences in the reduction levels 
between the two cell lines might be due to the differences in the nature of the cells. HCT-116 is 
colorectal cancer cell line, while T47D is a breast cancer cell line. Also, both cell lines expressed 
G UI mRNA at different levels.
Transfecting cells with 100 nM concentration of SI also showed four-fold reduction in GUI 
mRNA levels in T47D cells, while there was no change in GUI mRNA levels in HCT116 cells. 
This lack of effect on HCT-116 could be due to the stronger physical interaction of CRD-BP- 
GLI1 mRNA in these cells, and that a higher competitor concentration is required.
Another surprising observation was the reduction in GUI mRNA levels after transfecting 
T47D cells with 100 nM S4 oligonucleotide. This was unexpected because S4 was expected to
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serve as a negative control. Although this reduction level was less than the reduction levels 
exerted by SI oligonucleotide, there is a possibility that lower concentration of S4 might show 
competition in binding to CRD-BP or it may act via another mechanism. Nevertheless, it is not 
unusual to see differences in results generated in-vitro and in cells. Experiments conducted in 
vitro contain only CRD-BP, [32P]-labeled RNA and competitor oligonucleotides. However, cells 
contain many other proteins and RNAs which can interfere with the function of the 
oligonucleotide. In addition, there exist many different pathways in cells that might directly or 
indirectly affected by the oligonucleotide which in turn affected the results.
I propose that the reduction in GUI mRNA level by SI oligonucleotide was due to its ability 
to break CRD-BP-GZJ7 mRNA interaction in cells. To confirm this, immuno-precipitation 
experiments using IMP1 polyclonal antibody coupled with RT-qPCR to measure the levels of 
GUI mRNA physically associated with the endogenous CRD-BP will be required.
5.7 Future Direction
Studies reported in this thesis have paved many different ways to better understand the 
physical interaction between CRD-BP and its RNA targets. As the binding regions of GUI and 
MDRl RNAs have been mapped, one of the next steps could be the screening of small molecules 
for ability to break the physical interaction between CRD-BP and GUI and MDRl RNAs using 
high-throughput fluorescence polarization assay. Similar study has recently been initiated (Lily 
et al, 2013). The information on the smallest RNA sequences of GUI and MDRl RNAs can now 
be added to the list of RNA binders of CRD-BP. This should aid in in-silico analysis in 
understanding what common structure and sequences, if any, amongst the RNA binders of CRD- 
BP.
Few deletion studies on CRD-BP orthologs have been performed in an effort to understand the 
role played by each of the KH domains in binding RNA substrates (Git and Standart, 2002;
91
Chapter 5. General Discussion
Oberman et al., 2007; Farina et al, 2003; Chao et al., 2010). Point mutation studies conducted in 
Dr. Lee’s lab’s showed that c-myc and CD44 RNAs bind differently to CRD-BP (Barnes et al, 
submitted). Further mutational studies involving mutation in multiple regions within a single KH 
domain or multiple mutations in different KH domains can be done to get a deeper insight into 
the role played by individual amino acids in binding to RNA. X-ray crystallography studies on 
CRD-BP-RNA complex can be performed to observe the interaction between amino acids of 
protein and nucleotides of RNA at the atomic level.
The SI RNA oligonucleotide disrupted CRD-BP-GL/7 RNA interaction in vitro and reduced 
GUI mRNA levels in cells. Immunoprecipitation coupled with RT-qPCR can be performed to 
confirm that the ability of SI oligonucleotide to reduce GLI1 mRNA in cells is through its ability 
to disrupt CRD-BP-GZJ7 mRNA interaction. Western blot analysis can be performed to 
examine GLI1 protein levels after transfecting cells with SI oligonucleotides. MTT assay can be 
performed after transfecting cells with SI, to observe possible phenotypic changes in cancer cells 
which express high GUI mRNA levels. Anticancer drug resistant cells have been shown to 
become drug sensitive after depletion of GLI1 (Bhuvaneswari et al, 2012). Therefore, drug 
sensitivity assays can be performed after transfecting drug resistant cancer cells with SI 
oligonucleotide. SI oligonucleotide can be tested in other cancer cell lines to compare its ability 
to break specific CRD-BP-GL/7 interaction in different types of cancer cells. Finally, animal 
studies can be performed to observe the effect of SI oligonucleotide in vivo.
There is possibility of reduced mRNA levels of other CRD-BP target mRNAs such as CD44, 
c-myc, MDRl, k-ras etc. after transfecting cells with SI oligonucleotide. RT-qPCR can be 
performed to determine their mRNA levels. These studies should provide information about the 
specificity of the SI oligonucleotide.
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GUI is an important member of the Hh signaling pathway and a transcription factor that 
regulates expression of other targeted genes (Lee and Fredrick, 2006). Down regulating GUI 
will affect the Hh pathway as well as other related pathways under the control of G UI 
expression. Hence, the strategy to break specific CRD-BP-GZJ7 RNA interaction can be 
potentially used as a new therapeutic approach to treat cancer.
5.8 Concluding Remarks
In the light of above discussion, we can conclude that CRD-BP binds to different mRNA 
targets distinctly. This is a very important finding because this means that specific CRD-BP- 
mRNA interaction can be selectively disrupted by designing or discovering oligonucleotides and 
small molecules. This work also shows that the disruption of CRD-BP-mRNA interaction can 
result in the reduction of specific mRNA levels in cancer cells, which can ultimately lead to the 
reduction of the cancer phenotype. In short, breaking CRD-BP-RNA interaction has the potential 
to become a novel therapeutic strategy to treat cancer in the near future.
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Appendix
Calculation of Kd values:
Percentage of bound RNA was calculated using optiquant software as shown in Fig below.
A B
CRD-BP (nM) 0 147 294 426 735 900 0 147 294 426 735 900
C
CRD-BP (nM) 0 147 294 426 735 900
Fig 1. Optiquant software used to calculate bound and free RNA concentration.
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Table 1. Data showing %bound GLI1 RNA in all three gels.
%Bound %Bound %Bound Average Standard Deviation
Protein (nM) Gel A Gel B GeIC
0 0 0 0 0 0
147 13.4 34.7 20 22.7 10.90366911
294 43.2 55.1 48.1 48.8 5.980802622
426 70 51.7 46.7 56.13333 12.26634963
735 74.3 83.8 72.5 76.86667 6.071518207
900 84.3 73.1 90.4 82.6 8.774394566
Table 2. Concentration of WT-CRD-BP protein and percentage of bound RNA are given in 
Table below. (n=3)
WT-CRD-BP Concentration (nM) Percentage Bound
147 22.7±10.90
294 48.80±5,98
426 56.13±12.26
735 76.86±6.07
900 82.6±8.77
100 r
% Bound
y = ({1/m1)‘ (mOAm2))/(1+({1/.
Value
1.7968 0.0066455
R 0.99646
Protein Concentration (nM)
Fig 2. Saturation binding curve of WT-CRD-BP with GLI1 mRNA based on data given in Table 
2 .
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After finding out bound and free RNA concentration, Hill equation was used to calculate IQ 
value. Hill equation is given below.
bound _
1 5 5 * r ”  < + ((£)!«)*
Hill E quation
Kd= Dissociation constant 
L -  CRD-BP concentration 
u — Hill coefficient
